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ABSTRACT 
 
ROLAND CHEUNG: Antibody Carriers of CpG Oligodeoxynucleotides for Solid Tumor 
Immunotherapy 
(Under the direction of Moo J. Cho, Ph.D.) 
 
The use of CpG oligodeoxynucleotide (ODN) TLR9 agonists for oncology therapy 
has been primarily limited to its use as an adjuvant in combination therapies.  Successful 
anti-cancer therapy has been limited to the intratumoral and peritumoral routes of 
administration.  Subcutaneous (SC) administration has showed promise, but results have 
been modest at best.  For cancer monotherapy with CpG, we developed a delivery system 
utilizing an endogenous antibody as a carrier for CpG ODNs.  Our system first involves 
conjugation of a small molecule 2,4-dinitrophenyl (DNP) hapten to CpG.  Next, we 
immunize mice against the hapten such that a high titer of anti-DNP antibodies is maintained 
in the systemic circulation.  Upon injection of DNP-CpG, an immune complex will be 
formed.  Subsequently, the immune complex will be taken up by dendritic cells for CpG 
processing by TLR9 endosomal receptors. 
This system was shown to be effective in tumor growth inhibition in our animal 
model upon intravenous (IV) delivery of CpG ODNs, an administration route that has never 
shown to be effective.  In the following investigations, we found that the SC route of 
administration exhibited great efficacy.  Anti-tumor response was as good as IV delivery and 
showed an improvement over SC administration of underivatized CpG. Pharmacokinetic 
analysis suggests that increased half-life of CpG may play a role toward the therapeutic 
 iv
effect.  In vitro studies suggest that our immune complex effectively activates dendritic cells 
and that this effect is possibly due to facilitated processing of the immune complexes via Fc 
receptor-mediated endocytosis and not due to the extent of CpG uptake.  Based on collective 
results, we proposed mechanisms by which we were able to garner such a positive 
immunological response.  Additional opportunities stemming from this work will certainly be 
of great value.  The establishment of SC and IV formulations that exhibit desirable properties 
carries tremendous implications for the deliver of other therapeutic agents. 
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   CHAPTER I 
  
INTRODUCTION 
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Historical Perspective 
It has been observed for hundreds, and perhaps even thousands of years, that cancer 
patients who developed concurrent pathogenic infections would experience remissions of 
their malignancies.1  Many surgeons in the 1800s noted the link between erysipelas infections 
(a superficial infection of the skin caused by Streptcoccus pyogenes) and cancer remissions, 
but years would pass before a breakthrough in active cancer immunotherapy.  In 1891, Dr. 
William B. Coley, then a young surgeon at New York Memorial Hospital, experienced great 
distress from the loss of a female cancer patient.  Frustrated with the failure of surgery, he 
spent numerous hours examining all records of sarcoma cases at New York Hospital hoping 
to find alternative treatments.  Coley eventually discovered a seven-year-old record 
describing a man with sarcoma of the neck whose case was deemed hopeless after multiple 
failed surgeries.  The patient's last surgery resulted in a severe infection of erysipelas and 
high fever, but the man survived the infection and the tumor healed completely.  Coley spent 
weeks eagerly searching for this patient in lower Manhattan's east side slums and found him 
in good health and free from cancer. 
Coley's interest in erysipelas led him to discover historical literature and other 
publications that recorded similar findings linking acute infections with tumor regression.  
He then decided to treat cancer patients by infecting them with erysipelas.  Some cases met 
with great success, even after metastasis, but limitations to the treatments soon became 
apparent: some patients never developed an infection while others developed an infection so 
severe that they proved to be fatal.  Coley also observed that inducing a febrile response was 
vital in producing anti-cancer effect.  
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To address these difficulties, Coley eventually developed a vaccine comprised of two 
heat-killed bacteria: the Gram-positive Streptococcus pyogenes and Gram-negative Serratia 
marcescens.  This vaccine became known as “Coley's toxins”.  Although thousands of 
patients were treated with Coley's toxins, responses to the vaccine were still highly variable 
and depended on many factors including cancer type, route of administration, and precision 
of the vaccine formulation.  Eventually, after Coley's death in 1936, use of his vaccine 
diminished as radiation and chemotherapy became the preferred methods of treatment.  As a 
result of the Kefauver Harris Amendment in 1963, the Food and Drug Administration gave 
Coley's toxins “new drug” status, making it illegal to sell them in the United States. 
Thanks to the efforts of Coley's daughter, Helen Coley Nauts, and Wayne Martin, a 
chemical engineer who had a great interest in medicine, doctors and researchers developed a 
renewed interest in Coley's toxins.  In line with contemporary regulations and advances in 
medical research, the need and desire for a more refined and better understood method of 
cancer treatment has led to the eventual development of CpG oligodeoxynucleotides (ODNs). 
 
CpG Oligodeoxynucleotides and Toll-like Receptor 9 
Until the 1980s, the active bacterial component in Coley's toxin was thought to be 
lipopolysaccharide.  A Japanese research group working with Bacillus Calmette-Guerin 
(BCG), a vaccine against tuberculosis that is prepared from a strain of the attenuated live 
Mycobacterium bovis, found that the anti-tumor activity came from bacterial DNA.2-4   
Arthur Krieg's work in the 1990s contributed greatly to the understanding of the 
 4
immunotherapeutic effects of bacterial DNA and the design of short, synthetic DNA 
sequences meant to mimic bacterial DNA for the induction of selective immune responses. 
The vertebrate immune system recognizes invading pathogens using pattern 
recognition receptors.  The Toll-like receptors are among the most well-characterized 
receptor family with Toll-like receptor (TLR) 9 established as the receptor that recognizes 
and processes bacterial DNA.5,6  The ability of this receptor to distinguish between 
prokaryotic and eukaryotic DNA comes from a fundamental evolutionary differences.  TLR9 
recognizes and is activated by cytosine-phosphate-guanine (CpG) dinucleotides which are 
unmethylated and common in bacterial DNA, but are found methylated and with suppressed 
frequency in the vertebrate genome.7 
Knowledge of this has fueled the development of immunostimulatory CpG ODNs, 
also known as TLR9 agonists.  These short, synthetic DNA oligodeoxynucleotide sequences, 
ranging from eight to 30 nucleotides long, contain unmethylated CpG dinucleotides in 
specific base contexts called CpG motifs.  Specific modifications such as those to the sugar, 
base, backbone, and number of CpG, can be made to selectively elicit a type and the degree 
of an immune response.8  For example, CpG ODNs usually contain phosphorothioate (PS) 
modifications to the backbone to hinder nuclease degradation.  CpG ODNs are currently 
classified into one of four classes: A, B, C, and P.  To date, most of the vaccine work has 
utilized B-class CpG ODNs.  Class B is potent in producing IFN-α and B-cell activation and 
most well characterized in terms of anti-tumor activity and mechanism.7,9   For many murine-
based in vivo and cellular experiments, the B-class CpG ODNs used is CpG 1826.  It is a 
well-established ODN specifically developed for mouse studies and has the following 20-mer 
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sequence with two CpG motifs: 5'-TCCATGACGTTCCTGACGTT-3'.  A commonly used 
control is the non-CpG-containing ODN, ODN 1982, which has identical base composition 
as 1826, but ordered in a non-stimulatory sequence: 5'-TCCAGGAGTTCTCTCAGGTT-3'. 
TLR9 activation results in a cascade of innate and adaptive immune responses.10  
Since dendritic cells (DCs) act in the initiation of primary responses and as the interface 
between the two arms of the immune system,11 they are logical targets for CpG ODN 
delivery. 
 
Dendritic Cells and the Immune System 
Dendritic cells are the most potent of antigen presenting cells (APCs) and specialize 
in antigen presentation.11,12  Immature DCs originate from bone marrow and migrate 
throughout the body.  DCs exist in all lymphoid and most non-lymphoid tissues and, with 
high endocytic capacity, continuously sample their environment for foreign antigens.  There 
are multiple means by which DCs capture antigens: phagocytosis, macropinocytosis, 
pinocytosis, and receptor-mediated endocytosis.13  
When activated, DCs follow the unidirectional flow of the lymph through the 
lymphatic vessels until they reach the secondary lymphoid organs such as the lymph nodes 
where they will interact with T cells.14  DCs are so effective at stimulating the immune 
system because of their ability to interact with natural killer (NK) cells of the innate arm and 
with CD4+ (T helper cells) and CD8+ (Cytotoxic T cells, CTL) T cells of the adaptive arm.15  
The major histocompatibility complex (MHC) molecules, known in humans as the human 
leukocyte antigen (HLA), are the molecules that present the antigen to T cells.  The two 
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types, MHC class I and MHC class II, are distinct in their involvement in antigen processing.  
MHC I presents antigen fragments derived from cytosolic proteins to CD8+ T cells.  MHC II 
presents antigen fragments derived from exogenous proteins to CD4+ T cells.  MHC II 
antigens come from extracellular pathogens which have been endocytosed.  DCs are unique 
because they can effectively use MHC I to also present exogenous antigen fragments to 
CD8+ T cells through a specialized cross-presentation mechanism.16 
Plasmacytoid dendritic cells (pDCs), a subset of immature DCs, and B cells are the 
only human immune cells known to constitutively express TLR9 (Figure 1.1).17  When 
activated by CpG ODNs, pDCs excrete cytokines and chemokines which activate cells of the 
innate immune system which can confer direct anti-tumor effects.18-20  DC stimulation also 
results in increased expression of co-stimulatory molecules such as CD80 and CD86 to signal 
proliferation of T-cells, particularly type 1 helper T cells (TH1).  In the presence of tumor-
associated antigens, DCs can process these antigens for MHC presentation to T cells.  Both 
the co-stimulatory and MHC signals are required for successful activation of T cells.21   
Suggestive of DC involvement in CpG ODNs therapy, intralymphatic administration 
considerably improved therapeutic response to CpG ODNs22 while another study was able to 
treat large murine tumors using combined DC and CpG ODNs therapy.23  Still others have 
attempted to use receptor-mediated delivery of antigens to DCs for anticancer applications.24   
These findings warrant the use of CpG ODNs for dendritic cell activation, ultimately 
resulting in T cell effector function,25 in cancer immunotherapy.  As such, delivery of CpG 
ODNs to DCs would benefit greatly using a drug delivery system.  
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Endogenous Antibodies as Drug Carriers 
A major concern with current synthetic delivery systems is the inherent 
immunogenicity.26  Even some protein therapeutics can elicit immune responses and attempts 
have been made to minimize their immunogenicity.27  The ideal drug delivery system must 
not only carry intact cargo to the target location, but avoid activating the immune system or 
undesired neutralization that leads to elimination from the body.  Herein lies the enormous 
potential of endogenous antibodies in CpG ODNs and general delivery.  For example, DCs, 
in addition to TLR9, express cell-surface Fc receptors such as FcγR which bind the Fc 
domain of immunoglobulin G (IgG) antibodies.  This implicates the potential for IgG to be 
used for delivery to DCs.  Because of this and other desirable properties, natural and 
synthetic antibodies have been developed for many applications in medicine and research.  In 
fact, more than 20 antibody products are approved by the U.S. Food and Drug 
Administration (FDA).  Typically, the antibody itself is the therapeutic entity.  CpG ODNs 
have been used to boost the therapeutic effect of an antibody treatment,28 but only recently 
has the opposite been done: using antibodies to support the activity of CpG ODNs.29 
Antibodies, also called immunoglobulins (Igs), are serum glycoproteins which all 
have the same basic structure of two identical heavy chains and two identical light chains 
held together by disulfide bonds in a 'Y' shape (Figure 1.2).  They are naturally-occurring 
proteins produced and secreted by B cells of immune system to neutralize or destroy ligands 
to which they bind.  Human Igs have two types of light chains, κ and λ, but are classified into 
five families, or isotypes, based on their heavy chain: immunoglobulin α (IgA), δ (IgD), ε 
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(IgE), γ (IgG), and µ (IgM).  The isotypes differ in size, overall structure, and antigen binding 
sites.  
Of all Igs, IgG makes up approximately 80% of the total at an average concentration 
of about 10 mg/ml and a maximum concentration as high as 17 mg/ml in the blood, making it 
the second most abundant blood protein after albumin.  Most, if not all, therapeutic 
antibodies to date are of the IgG class.  An example of IgG's role in protective immunity is its 
natural function in providing passive humoral immunity to a fetus from the mother.  Based 
on structural differences of the heavy chains, which allow for differences in receptor binding, 
IgGs can be further divided into four subclasses: IgG1, IgG2, IgG3, and IgG4.  Each intact IgG 
has a high molecular weight of approximately 150 kDa.  Each light chain is around 25 kDa in 
size and each heavy chain is about 50 kDa.  A single IgG molecule has two identical antigen-
binding domains, or Fab (fragment of antigen binding), and an Fc (fragment crystallizable) 
domain.  The Fc domain is involved in the binding to a variety of cell-surface receptors. 
Not only is the neonatal Fc receptor (FcRn), specific for the transport of IgG, 
important in conferring passive immunity from mother to fetus, it plays an important role in 
IgG homeostasis.  Also known as the Brambell receptor, FcRn protects viable IgG from 
catabolism and allows IgG to be recycled via endocytic pathways thereby giving IgG a long 
circulatory half-life (t1/2) of greater than 21 days in humans. 
The FcRn protection pathway initially involves the uptake of IgG into various cells 
via non-specific fluid phase pinocytosis.  As the endosome matures, a characteristic decrease 
in pH follows which provides a favorable condition for viable IgG binding to FcRn.   
Eventually, the endosome fuses with the lysosome and unbound IgG will be digested by 
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proteases.  The IgG-FcRn complex is trafficked back to the cell surface when the endosome 
fuses with the plasma membrane.  Exposure to the physiological pH causes the complex to 
disassociate, releasing IgG back into the plasma or interstitial fluid.30-32 
Upon IgG binding to an antigen, however, different processing pathways can occur.  
A polymeric antigen-IgG immune complex (IC) is subject to degradation in the lyosomes 
after FcRn-mediated uptake.33  However, a 1:1 antigen-IgG immune complex (IC), being 
structurally similar to free IgG in that it cannot crosslink antigen, is subject to uptake via 
FcγR-mediated endocytosis into APCs such as DCs.  There are three types FcγR on various 
immune cells that recognize the Fc domain of IgG molecules, each showing a different 
affinity for IgG or IgG-containing ICs.  Of the three, only FcγRI (CD64) processes 
monomeric ICs34,35 and exhibits a high affinity (10-9 M) for IgG.36  As a result of their ability 
to recognize their specific antigen, they have been exploited for their effector function or 
targeted drug delivery.  A highly unique approach is to use them as a drug carrier for 
therapeutic compounds that otherwise would exhibit undesirable pharmacokinetic (PK) 
profiles, such as CpG ODNs.  
Constitutive fluid-phase endocytosis including macropinocytosis is energy-
consuming and non-specific in solute uptake.  The process diminishes significantly as the DC 
matures.37  The rationale behind the use of FcγR in delivering CpG in a monovalent IC is 
supported by the discovery that the FcγRs expressed on DCs can effectively take up and 
process ICs38 and are involved in the efficient priming of TH cell responses in vivo.39  Indeed, 
a DNA vaccine comprised of an antigen fused to an IgG Fc fragment40 and ovalbumin/anti-
ovalbumin ICs successfully demonstrated both major histocompatibility complex (MHC) I- 
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and II-derived responses when targeted to DCs in mice.41  Several in vitro studies have 
shown that DCs present IgG-complexed antigens more effectively to CD8+ T and CD4+ 
cells than soluble antigens.42,43  In a murine tumor model, treatment has been shown to be 
more effective using DCs which have been pre-loaded ex vivo with ICs compared with direct 
injection of soluble ICs.44 
Unlike the often intensive and difficult synthetic process required to develop 
nanoparticulate carriers, antibodies can be produced in high quantities through both in vivo 
and in vitro methods.  Monoclonal antibodies (mAbs) are extensively used in basic research, 
diagnostics, and as therapeutic agents for cancer, inflammation, and infectious disease.  The 
monoclonal antibody production process permits large quantities of antibodies targeted 
against a particular antigen to be produced.  Initially, a mouse is immunized by injection of 
an antigen to stimulate the production of antibodies targeted against the particular antigen.  
The antibody-secreting B cells are isolated from the spleen.  Monoclonal antibodies are 
produced by fusing a single B cell to a tumor cell and this generated hybrid cell, hence called 
a hybridoma, is then grown in culture.  By allowing the hybridoma to multiply in culture, a 
uniform population of cells is produced, each of which produces identical antibody 
molecules.  These antibodies are called monoclonal antibodies because they are produced by 
the identical offspring of a single, cloned antibody-secreting cell.  Hybridoma cells can be 
grown using two methods.  A major benefit using hybridomas is that they can be cultured 
indefinitely in cell culture media.  Alternatively, the cells can be injected into the peritoneal 
cavity of mice where they produce tumors containing an antibody-rich fluid called ascites 
fluid.  Although mAb production is constant, offers high concentration, purity, and 
homogeneity, monospecificity sometimes limits their use and production often requires more 
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time, skill, and money relative to polyclonal antibody (pAb) production.  Monoclonal 
antibody usage as drug carriers in humans may not be ideal since murine mAbs in humans 
have been shown to only have serum half-lives of one to two days45,46 and can be 
immunogenic.  Even humanized, or chimeric, mAbs do not have the same ideal PK 
properties as fully human IgGs.  However, there is promise in utilizing mAbs as drug carriers 
since fully human mAbs have recently been produced through advanced genetic 
manipulations.47 
Polyclonal antibodies are produced by immunizing an animal against a particular 
antigen and, if desired, are then isolated from collected blood.  The concentration of antigen-
specific antibodies ranges from 50 to 200 µg/ml although absolute quantity is dependent on 
the size and age of the animal.48  Due to aforementioned issues with mAbs, pAbs are a 
promising alternative for drug delivery.  Artificial active immunization involves injection of 
an antigen into the host to elicit production of antigen-specific IgGs in a large excess of 
antigen.  The resulting stoichiometric excess of antibody to antigen is desirable for sustained 
immune complex formation. 
 
Passive Tumor Targeting and the EPR Effect 
Antibody usage in drug delivery has enormous potential.  Not only can antibodies 
bind cargo and deliver it to DCs, they can be used in passive tumor targeting.  The enhanced 
permeability and retention (EPR) effect is a phenomenon described over 20 years ago for 
passive targeting of macromolecules to solid tumors.49  Tumors trigger angiogenesis and 
maintain a high density of vessels to obtain the vast amount of oxygen and nutrients 
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necessary to sustain their growth.  Unlike in normal tissues, the neovasculature exhibits 
abnormal vascular architecture.  These defective vessels are leaky due to large openings 
called fenestrae which can range from 100 to 600 nm.50  The lack of a smooth muscle layer 
results in irregular blood flow.  Impaired lymphatic clearance51 and reduced venous blood 
flow in the tumor leads to retention and accumulation of macromolecules and 
nanoparticles.52  
Tumor targeting strategies based on the EPR effect have been reported with soluble 
polymeric drugs53,54 as well as particulates such as liposomes.55  A standard explanation is 
that macromolecules or particulates are passively trapped in partially denuded endothelium.   
A major weakness in this argument is the failure to recognize potential competition with a 
large excess of endogenous macromolecules such as immunoglobulins and albumin and 
particulates such as platelets and lipoprotein particles.  Furthermore, synthetic nanocarriers 
require meticulous design for size control since they must avoid the major clearance 
mechanisms.  The kidneys are known to filter compounds with molecular weighs less than 
about 70,000 daltons (Da) and particles less than 10 nm in size whereas those greater than 
100 nm are subject to clearance by the liver.56  Nanoparticles must also be shielded from the 
reticuloendothelial system (RES), a system of phagocytic cells found in the circulation and 
tissue, primarily comprised of monocytes and macrophages, which engulf and destroy 
foreign or abnormal cells and substances. 
Interstitial transport of macromolecules from the site of retention in the endothelium 
to tumor interior can be unfavorable. This is because the interstitial transport of 
macromolecules and particulates is mainly via solvent drag (i.e. convection) and because 
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high interstitial fluid pressure and elevated oncotic pressure, a result of impaired lymphatics 
in the tumor, would work against the convective transport.57,58  The dilemma of the large size 
needed in exploiting EPR effect and the small size desirable for interstitial transport could 
well be the reason for the poor in vivo outcome of many tumor-targeted macromolecular drug 
delivery strategies that otherwise have shown tremendous potential in cellular systems.  
In the proposed use of IgG as a carrier, the dilemma is largely avoided as our target is 
not tumor cells per se but DCs in the tumor vicinity.10  Therefore, it may not be required for 
our CpG-containing ICs to penetrate deep into the tumor tissue.  All in all, the multitude of 
benefits that antibodies can provide may offer an enhanced synergistic effect for anti-tumor 
therapy. 
 
Routes of Administration 
To date, CpG ODNs use in monotherapy continues to be limited. Although intra- and 
peri-tumoral injections have been effective in murine models,10 these routes limit the use of 
CpG ODNs to only specific types of cancer.  Intravenous (IV) administration is often used 
because the drug has 100% bioavailability such that maximum absorption and distribution is 
ensured.  However, IV delivery of any ODN results in rapid clearance from the circulation to 
the clearing organs, particularly the liver and kidneys.  IV dosing also subjects ODN to 
dilution and non-specific binding to serum proteins.  Only recently has it been shown that it 
can be effective in anti-cancer therapy after intravenous administration.29  
Due to the failed attempts of intravenous CpG ODNs delivery, the subcutaneous (SC) 
route of administration has been studied although not established for monotherapy.7,59,60  SC 
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administration offers many practical benefits. IV and intramuscular (IM) injections require 
skilled personnel whereas SC injections can be self-administered by a patient and can be 
painless.  In fact, many drugs such as insulin and heparin have been highly successful 
through SC administration.  The SC route is very promising especially since it allows for 
slow release from the injection site and for accumulation in the lymph nodes where many 
DCs are located. 
Development of tumor vaccines using CpG ODNs monotherapy has not been 
successful although use of CpG ODNs as adjuvants61-63 or in multi-modal treatments show 
clinical promise.64,65  The importance of delivery route was recently manifested by Pfizer’s 
decision not to develop CpG 7907 (also known as PF-3512676) any further in treating non-
small cell lung cancer, after the initial human clinical studies show no clear-cut efficacy with 
a systemic route of administration (http://www.forbes.com/healthcare/2007/06/20/pfizer-
coley-drug-biz-bizhealth-cx_mh_0620pfizer.html). The following drug delivery strategies 
were devised to resolve issues with CpG delivery regardless of administration route. 
 
Development of a Drug Delivery System 
In order for IgG to be used as a CpG ODNs carrier, major considerations must be 
taken into account.  IgG must recognize and bind specifically to CpG ODNs with a high 
enough affinity such that the cargo is not subject to clearance mechanisms before it reaches 
the DC targets, but also must bind in such a way that does not obstruct its uptake by DCs nor 
obstruct binding of CpG ODNs to TLR9.  To maximize binding, IgG would ideally exist in 
large excess such that 100% of administered CpG ODNs is bound.  A 1:1 or 1:2 
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stoichiometric ratio of IgG to ligand, such that either one or both Fab domains are occupied, 
would confer an apparent IC t1/2 similar to that of the antibody itself.66-70  Initially, it would 
appear that ICs containing CpG as an antigen would eliminate the CpG ODN rather than 
extending its circulation time.  In reality, IC formation can have a wide range of PK effects 
on the bound antigen depending upon the size of the antigen, the stoichiometry of the IC, and 
the titer of the antibody.70  Antigen crosslinking must be avoided since polymeric ICs not 
only neutralize the cargo, but are themselves subject to enhanced clearance.  Monovalent ICs, 
however, do not induce antigen crosslinking and enjoy a prolonged life time.  This PK 
property has been utilized in the systemic delivery of small molecules69 as well as proteins,68 
and may also be applied to ODN delivery.  
Binding of IgG to CpG ODNs can readily accomplished by simple chemical 
modification (Figure 1.3).  The most straightforward method is to add a hapten to CpG. 2,4-
Dinitrophenyl (DNP) moiety can easily be conjugated to CpG ODNs through a linker during 
automated solid-phase ODN synthesis.  This small molecular-weight hapten lacks any 
inherent immunogenicity and mono-derivatization on CpG ODNs avoids crosslinking.  Since 
any chemical modification at the 5’-end of CpG ODNs reduces their immune-stimulating 
activity,8 DNP is introduced only at the 3’-end.  Logically, an anti-DNP antibody would need 
to be used.  For in vitro and mechanistic studies, anti-trinitrophenyl (TNP) mIgG1 from 
1B7.11 and IGEL a2 hybridoma cells and anti-DNP IgG1 from ANO6 hybridomas are 
available.  For in vivo polyclonal antibody production against a specific antigen, standard 
immunization protocols have long been established.  Antigens are usually proteins or 
polysaccharides.  In order for smaller molecules such as DNP compounds to become 
antigenic, multiple molecules are extensively conjugated to large carrier proteins, such as 
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albumin or keyhole limpet hemocyanin (KLH).   A primary injection of this highly 
derivatized carrier protein along with an adjuvant via a relevant administration route into the 
host will trigger antibody production against the antigen.  Additional injections, called 
boosters, can be administered at regular time intervals to maintain a high antibody titer. 
The strength of association is one variable that can easily be controlled to improve 
serum t1/2 in vivo and has been optimized for the effects of several variables on the total 
interactive energy, or avidity, between anti-DNP monoclonal antibody and DNP-modified 
ODNs.67  Monovalent 1:1 ICs indeed exhibit a long circulation t1/2, providing a sufficient 
time for tumor accumulation in DNP-immunized mice whereas ICs with CpG haptenized 
with two DNP (DNP2-CpG ODNs) showed increased clearance possibly due to polymeric IC 
formation.29  Perhaps more importantly, the Fc domain of the ICs appears to promote their 
entry to DCs thereby facilitating DC activation.  
Since IgG is found ubiquitously throughout blood and tissue alike, CpG can be 
injected via multiple routes of administration to form ICs after active immunization. A 
substantial amount of endogenous IgG is found in the interstitial tissue in dynamic 
equilibrium with plasma, approximately at 25% of the plasma concentration.71  Therefore, 
regardless of most administration routes, CpG ODNs is expected to remain as ICs which will 
eventually find their DC targets (Figure 1.4). 
 As a proof on concept, we first employed our system for intravenous delivery.29  In 
the first pharmacokinetic study using this endogenous immune complex system, 
underivatized CpG administered intravenously to non-immunized, tumor-bearing mice 
exhibited rapid clearance with almost complete elimination after only two hours.  In contrast, 
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DNP-derivatized CpG administered to DNP-immunized, tumor-bearing mice showed a long, 
sustained systemic circulation with high serum levels even after 72 hours (Figure 1.5).  The 
PK properties of DNP-CpG were highly favorable.  Compared to free CpG, DNP-CpG had a 
266-fold increase in elimination half-life, a 1650-fold increase in systemic exposure, a 13-
fold decrease in the tissue volume of distribution, and a 1530-fold decrease in systemic 
clearance.  DNP2-CpG, a CpG derivative which contains two DNP haptens was used to 
determine whether a greater binding affinity to the anti-DNP antibody could confer 
additional improvements in PK properties.  Although DNP2-CpG showed better PK 
properties than free CpG, DNP-CpG improvements were much greater (Table 1).  Since 
DNP2-CpG has two DNP haptens, antibody crosslinking could have occurred which 
subsequently led to the rapid elimination of such polymeric immune complexes.  Based on 
this finding, all further studies utilized DNP-CpG. 
 Analysis of the biodistribution of free CpG shows that the ODN is found primarily in 
the clearance organs while only up to 2% of the injected dose is found in the tumor tissue at 
any given time.  In contrast, tumor accumulation of DNP-CpG was up to 10-fold higher with 
over 20% of the injected dose found in the tumor tissue.  A high percentage of the dose was 
sustained in the tumor tissue even after 72 hours (Figure 1.6).  This finding supports the 
involvement of the EPR effect as we had proposed. 
 In a preliminary tumor growth inhibition study, PBS, free CpG, and DNP-CpG were 
intravenously administered to DNP-immunized, tumor-bearing mice.  Administration of free 
CpG did not result in any anti-tumor response and the rapid tumor growth pattern mirrored 
that of the PBS negative control.  DNP-CpG treatments, however, were able to inhibit the 
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rate of tumor growth, especially when the anti-DNP antibody titer was high (Figure 1.7).  
Around dose 3, the time when antibody titers dropped to low levels, treatments were no 
longer effective which attests to the need for immune complex formation. 
 In the following chapters, we further employ this intricately developed drug delivery 
strategy in the treatment of solid tumors and explore the possible mechanistic effects 
involved.  Our approach was already shown to be effective when treatments were 
administered intravenously.  Further studies confirm these previous results.  Furthermore, 
contralateral subcutaneous (SC) injections were also found to be effective in the same mouse 
model. One possible explanation of these successful outcomes was that we were able to 
provide: (1) sustained circulation of the CpG ODNs through spontaneous formation of 
monovalent ICs in vivo; (2) targeting of the CpG ODNs to DCs in the tumor margin via the 
EPR effect; and (3) facilitated uptake of ICs by DCs through the Fc receptor expressed on 
pDCs. 
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Figure 1.1  Activation of the immune system by CpG oligodeoxynucleotides.  This figure 
was borrowed from Krieg, AM.  CpG motifs: the active ingredient in bacterial extracts?  Nat. 
Med. 2003 9:831-835. 
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Figure 1.2.  Structure and function of immunoglobulin G.  IgG can be used as an endogenous 
protein carrier because it can be found in high levels in vivo, can bind drugs with high 
affinity, exhibits a long circulatory half-life and lack of antigenicity, and can target drugs to 
antigen-presenting cells via Fc receptor-mediated endocytosis. 
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Figure 1.3.  Haptenization of CpG for immune complexation.  DNP-CpG forms a non-
crosslinking complex with an anti-DNP antibody.  The CpG oligonucleotide contains a 
phosphorothioate backbone.  The complex exhibits characteristics similar to those of the 
antibody alone. 
5’-TCC ATG ACG TTC CTG ACG TT-3’
O2N
NO2
H
N O
O
O
O OH
O
P O-S
O
 22
 
            
Figure 1.4.  Proposed mechanism by which dendritic cells uptake and process a monovalent, 
non-crosslinking immune complexes.  Dendritic cells uptake the immune complex via FcγRI-
mediated endocytosis.  The complex dissociates in the acidic pH of the endosome.  The 
liberated CpG oligonucleotide binds to the endosomal receptor TLR9 to initiate an immune 
response. (Figure modified from Bell, E. Nat. Rev. Immunol. 2004, 4, 3-3) 
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Figure 1.5.  Serum pharmacokinetic profile of free CpG, DNP-CpG, and DNP2-CpG after a 
single intravenous dose.  Serum concentrations of [3H]-CpG-ODN in CT26 tumor-bearing 
mice and of DNP-[3H]-DNP-CpG and DNP2-[3H]-CpG-ODN in DNP-immunized, CT26 
tumor-bearing mice. The above oligodeoxynucleotides (2.8 nmole, 18-22 µg) were injected 
as an intravenous bolus via the tail vein. At specific time points, mice were exsanguinated by 
decapitation or cardiac puncture; collected blood was processed for serum and counted via 
liquid scintillation counting. n = 3 mice per time point.  Figure is from reference 29. 
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Table 1.  Serum pharmacokinetic parameters of free CpG, DNP-CpG, and DNP2-CpG after a 
single intravenous dose.  Table from E. Palma, “Antibody-Mediated Systemic Delivery of 
CpG Oligonucleotides for Solid Tumor Immunotherapy,“  PhD Dissertation submitted to the 
University of North Carolina, 2006 
* In non-immunized, tumor-bearing mice; control ODN is shaded gray
† Fold-change relative to control ODN.  Arrows indicate direction of change 
108 ± 21.6
(134 )
267 ± 138
(331 )0.807 ± 0.949MRT (hr)
0.0170 ± 0.00281
(746)
0.00825 ± 0.00385
(1530)12.6 ± 7.85CL (ml/hr)
1.83 ± 0.103
(5.59)
2.20 ± 0.159
(4.63)10.2 ± 6.26Vss (ml)
0.228 ± 0.194
(37.0)
0.657 ± 0.234
(12.9)8.46 ± 6.24V2 (ml)
1.60 ± 0.1671.54 ± 0.1721.75 ± 0.131V1 (ml)
1290 ± 214
(884 )
2410 ± 1120
(1650 )1.46 ± 0.903AUC (hr·µg / ml)
74.6 ± 15.0
(108 )
185 ± 95.8
(266 )0.694 ± 0.745t1/2,β (hr)
0.259 ± 0.519
(12.0 )
0.121 ± 0.200
(5.63 ) †0.0215 ± 0.00427t1/2,α (hr)
DNP2-[3H]-CpG-ODNDNP-[3H]-CpG-ODN [3H]-CpG-ODN*
Table 1. Serum pharmacokinetic parameters following a single intravenous bolus injection of [3H]-CpG-ODN, DNP-
[3H]-CpG-ODN, and DNP2-[3H]-CpG-ODN into DNP-immunized, tumor-bearing mice.
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Figure 1.6.  Biodistribution of DNP-CpG and free CpG after a single intravenous dose.  
Tumor-bearing mice were pre-immunized against DNP.  The colored bars represent the 
average percent of the total injected dose at given time points after the given dose.  n = 3 
mice per time point. A large amount was found in the clearance organs.  However, a very 
high percentage was found in the tumor tissue which supports the involvement of the EPR 
effect. See reference 29. 
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Figure 1.7.  Comparison of tumor growth inhibition between intravenous dosing of free CpG 
and DNP-CpG in immunized mice.  Tumor growth inhibition by PBS (negative control, 
n=7), free CpG (n=10), and DNP-CpG (n=10) administered intravenously in DNP-
immunized, CT26 tumor-bearing mice.  Tumor volumes were plotted against time in days 
after tumor inoculation.  Data are expressed as means ± SEM.  In the lower graph, the anti-
DNP titer after immunization with DNP-KLH along with Freund’s adjuvants is shown. n = 
10 mice. CT26 cell inoculation took place immediately after 6 weeks after immunization, 
marked by the first arrow. Mice were subsequently treated three times with DNP-CpG as 
indicated by subsequent arrows. Note that the titer did not increase with the DNP-CpG 
treatments, supporting that B cells were not activated with DNP-CpG treatment. See 
reference 29. 
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CHAPTER II 
 
PHARMACOKINETICS OF CpG OLIGODEOXYNUCLEOTIDES UPON 
SUBCUTANEOUS ADMINISTRATION IN MICE 
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Abstract 
 A prolonged circulatory half-life that will allow for a sustained supply to 
(intra)cellular targets are important in oligonucleotide delivery in its pharmacological 
intervention in a given disease state.  To confer favorable pharmacokinetic (PK) properties to 
our model CpG oligodeoxynucleotide (ODN), we have devised a 2,4-dinitrophenyl derivative 
of CpG ODN (DNP-CpG) which exhibits a favorable systemic half-life in the presence of 
endogenously produced anti-DNP antibodies.  We have previously shown that intravenously 
(IV) administered DNP-CpG exhibits prolonged circulation in vivo whereas underivatized 
CpG (free CpG) is rapidly eliminated. 
In this study, we characterized and compared the pharmacokinetics and 
biodistribution of underivatized [3H]-CpG and DNP-[3H]-CpG in DNP-immunized, CT26 
tumor-bearing mice upon subcutaneous (SC) administration.  Serum and tissue samples for 
PK and biodistribution analysis were collected at set post-dose time points for analysis by 
liquid scintillation counting.  In both cases, an absorption and elimination phases are 
apparent although DNP-CpG exhibits slightly faster peak serum levels and gradual 
elimination.  A high percentage of the injected dose remains in the injection site, but there is 
little accumulation in the tumor for both treatments.  These results characterize the 
differences between the subcutaneous administration of DNP-CpG in an immune complex 
(IC) forming system and free CpG. 
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Introduction 
  
Small oligodeoxynucleotides (ODN) that contain unmethylated CpG motifs can 
activate immune responses, providing potential applications in cancer and other diseases.1,2    
However, for CpG monotherapy to be effective in tumor models, these ODNs must be 
injected intra- or peri-tumorally.3  Recently, we were able to dramatically improve the 
pharmacokinetics (PK) of intravenously administered 20-mer CpG, known as CpG 1826 in 
the literature, by injecting its 2,4-dinitrophenyl (DNP) derivative to tumor-bearing mice that 
had been immunized against the DNP hapten.  More significantly, the intravenous 
administration inhibited tumor growth.4 
The PK behavior of the systemically administered ODNs with a phosphorothioate 
backbone is largely nucleotide sequence-independent, equivalent across non-human and 
human species on a normalized-dose basis.  It is thus accepted that animal PK study results 
can be extrapolated to humans.5  Upon bolus IV administration, these ODNs generally show 
a serum profile consisting of a rapid tissue distribution phase with a t1/2 of a few minutes 
followed by an elimination phase with a t1/2 of 15 to 45 min. The poor anti-tumor effect of 
intravenously administered CpG ODNs in mice3 and humans6 is possibly due to their poor 
uptake by target cells; i.e., the amount of the CpG delivered to target cells, such as dendritic 
cells, was insufficient.  This is in turn caused by the rapid renal clearance of this class of 
ODNs.7-9  One solution is to use an antibody carrier to exploit the enhanced permeability and 
retention (EPR) for passive targeting of CpG ODNs to dendritic cells.  Leaky vasculature and 
impaired lymphatics in the tumor vicinity will allow accumulation of antibodies and 
subsequent presentation of CpG ODNs to surrounding dendritic cells. 
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 In our preliminary studies, BALB/c mice were first immunized with DNP. They 
were subsequently inoculated with BALB/c-derived colon carcinoma CT26 cells. When the 
solid tumor was clearly palpable, [3H]-labeled DNP derivative of CpG 1826 ([3H]-DNP-
CpG) was injected via tail vein.  At a given time interval, CpG concentrations in blood, 
organs, and tumor tissue were determined.  These PK studies lasted for three days.  In a 
separate series of experiments but in a similar protocol, anti-tumor effect of DNP-CpG was 
continuously monitored over a 30-day period with weekly IV dosing. The 
PK/pharmacodynamic (PD) results are highlighted as follows.4  The serum elimination phase 
t1/2 increased from 0.69 hr for CpG to 185 hr for DNP-CpG, which is an increase of nearly 
270-fold. The t1/2 observed is in a reasonable agreement with the value for free IgG1 in 
mice.10,11   Accordingly, the mean residence time increased 330-fold.  The area under curve 
in serum concentration increased 1,650-fold.  Clearance decreased 1,260-fold.  In accordance 
of these extraordinary PK findings and the expected EPR effect, the fraction of injected dose 
(% ID) found in tumor tissue ranged from 10 to as high as 23% and persisted for 3 days.  
These numbers correspond to approximately 40 and 90 %ID/gm tumor, respectively.  In 
contrast, CpG accumulated less than 1% and not detectable after 2 hrs.  Weekly IV dosing of 
0.1 mg/mouse inhibited tumor growth when the initial tumor was on the average 175 mm3.  
To our best knowledge, this is the first time anti-tumor effect was successfully observed 
subsequent to the IV route of administration.  Tumor shrinkage was confirmed 
macroscopically as well as histologically.  Cell infiltration, presumably lymphocytes, was 
clearly noticed.  
 Since a substantial amount of endogenous IgG is found in the interstitial tissue in 
dynamic equilibrium with plasma, approximately at 25% of the plasma concentration12, we 
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reasoned that a significant amount of SC dose of DNP-CpG would exist as an IC at the 
injection site in the tissue. These complexes will be drained to lymphatics and eventually 
discharged to general circulation where a high anti-DNP titer is available for further IC 
formation.   In the present study, we investigated the PK and organ distribution including 
tumor accumulation subsequent to SC administration of DNP-CpG relative to unconjugated, 
free CpG in DNP-immunized, CT26 tumor-bearing mice. 
 
 
Experimental Procedure 
General Procedures and Materials 
All reagents were purchased from commercial sources and were used without further 
purification unless noted otherwise.  Forty female BALB/c mice, five weeks of age, were 
purchased from The Jackson Laboratory (Bar Harbor, ME).  All mice were housed in the 
UNC Eshelman School of Pharmacy Kerr Hall Animal Facility according to NIH guidelines. 
All procedures were approved by the UNC Institutional Animal Care and Use Committee.  
Molecular biology-grade water, phosphate buffered saline (PBS), sodium carbonate, 
thimerosal, Tween 20, ethylenediaminetetraacetic acid (EDTA), 30% H2O2 solution, β-
mercaptoethanol, Tris base, complete Freund’s adjuvant (CFA), and incomplete Freund’s 
adjuvant (IFA) were purchased from Sigma-Aldrich (St. Louis, MO).  Hammersten-grade 
casein was purchased from Research Organics (Cleveland, OH).  Dinitrophenylated keyhole 
limpet hemocyanin (DNP-KLH) was purchased from Calbiochem (San Diego, CA).  
BALB/c-derived colon carcinoma CT26 cells were purchased from American Type Culture 
Collection (ATCC) (Manassas, VA) and cultured in Dulbecco's Modified Eagle Medium 
(DMEM) with low (1 g/L) glucose supplemented with 10% fetal bovine serum (FBS) and 1% 
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penicillin/streptomycin.  All cell culture reagents, including trypsin-EDTA and Hank’s 
Balanced Salt Solution (HBSS) were purchased from Invitrogen (Carlsbad, CA).  Cell culture 
vented flasks and conical tubes were purchased from Corning, Inc. (Corning, NY).   
CpG 1826 (free CpG) and dinitrophenylated CpG 1826 (DNP-CpG) were synthesized 
with a phosphorothioate backbone and provided in lyophilized form by Dr. Rowshon Alam 
of the Nucleic Acid Core Facility of the Program Project Grant in Pharmacodynamics of 
Genes and Oligonucleotides at the University of North Carolina at Chapel Hill.  Solvable and 
Ultima Gold were purchased from PerkinElmer (Waltham, MA).  Ketamine HCl (Ketaved, 
100 mg/ml) used during PK experiments was provided by Dr. Philip Smith at the UNC 
Eshelman School of Pharmacy. 
 
Oligonucleotide Radiolabeling 
 Oligonucleotides were tritium labeled with [3H]-water (5 Ci/g; Sigma-Aldrich, St. 
Louis, MO) according to similar methods previously desccribeed.13  Five milligrams of DNP-
CpG in water was placed in a 1.0 ml Reacti-Vial (Pierce, Rockford, IL) and lyophilized 
overnight.  Two hundred microliters of 50 mM sodium phosphate containing 0.1 mM EDTA 
at pH 7.8 was added to DNP-CpG and lyophilized overnight.  Subsequently 200 µl of [3H]-
water was added to the dry DNP-CpG with 84 µl β-mercaptoethanol.  The reaction mixture 
was placed in an oil bath at 90oC for 6 hours.  The sample was then removed from the oil 
bath and lyophilized overnight.  Free CpG was radiolabeled similarly.  Specific activity (SA) 
and purity were determined to be in the range of 6.5-7.6 x 104 dpm/µg.  All ODNs were 
dissolved in sterile PBS prior to use in vivo. 
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Vaccine Preparation, Active Immunization, and Tumor Inoculation 
 To prepare the primary vaccine, 20 mg of DNP-KLH was dissolved in 10 ml of 
endotoxin-free water to give a 2 mg/ml solution.  Prior to vaccination, an equal volume of 
CFA was added.  The mixture was emulsified by vortexing at maximum rpm for 15 minutes 
using a multi-tube vortexer (VWR, West Chester, PA).  Secondary vaccines were prepared 
similarly, but replacing CFA with IFA. 
Forty BALB/c mice were immunized intraperitoneally with 200 µl of freshly prepared 
primary vaccine.  A booster injection was given two weeks later using 200 µl of the 
secondary vaccine.  Anti-DNP antibody titer was monitored by ELISA.  Four to five weeks 
after primary vaccination, DNP-immunized mice were inoculated with 2.5x105 CT26 cells 
suspended in 100 µl HBSS into the right flank.  Tumor growth was monitored daily. 
 
Pharmacokinetics and Biodistribution 
 On the ninth day after tumor inoculation, 18 mice were dosed subcutaneously in the 
left flank with 100 µg of [3H]-CpG (SA = 7.6x104 dpm/µg) in 100 µl of PBS.  At 5, 10, 20, 
60, 120, and 240 minutes post-dose, three mice per time point were anesthetized 
intraperitoneally with 100 µl of 100 mg/ml ketamine·HCl.  Additionally, 21 mice were dosed 
subcutaneously with 108 µg of DNP-[3H]-CpG (SA = 6.5x104 dpm/µg) in 100 µl of PBS.  At 
0.5, 2, 6, 12, 24, 48 and 72 hours post-dose, mice were anesthetized as described above.  
Mice were exsanguined by cardiac puncture and each blood sample was allowed to clot in a 
1.6 ml eppendorf tube for two hours at room temperature (RT).  Serum was collected after 
centrifugation of coagulated blood at 500 x g for 15 minutes and stored at -20oC for further 
analysis.  The injection site, heart, lungs, spleen, liver, kidneys, and tumor were subsequently 
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harvested, rinsed briefly with water, blotted dry, placed in pre-weighed 20 ml scintillation 
vials, flash frozen in liquid nitrogen, and stored at -80oC until analyzed. 
 Organ and tissue samples were processed as previously described14 with slight 
modifications.  Samples were thawed at RT and homogenized in 3 ml of cold homogenizing 
buffer comprised of 10 mM EDTA, 1 mM β-mercaptoethanol, and 100 mM Tris buffer at pH 
7.5 using a PowerGen 700 tissue homogenizer (Thermo Fisher Scientific, Waltham, MA) 
followed by addition of 2 ml of Solvable tissue solubilizer.  Vials were then heated 
overnight in a 60oC shaking water bath.  Solubilized organs were decolorized using 0.2 ml of 
30% H2O2 and heating once more at 60oC for 2 hours.  Vials were cooled to RT and 10 ml of 
Ultima Gold scintillation cocktail was added.  Serum samples were processed only by the 
addition of 25 µl of sample to 10 ml of scintillation cocktail.  The radioactivity in dpm of all 
samples was measured using a Packard Tri-Carb 2900TR Liquid Scintillation Analyzer and 
corrected for background radioactivity.  No additional correction was performed for organ-
associated quenching nor organ-associated radioactivity from resident blood volume. 
 
 
Results 
Serum concentration-versus-time data was derived from radioactivity measurements.  
As seen in Figure 2.1, biphasic pharmacokinetic profiles were observed for both [3H]-CpG 
and DNP-[3H]-CpG. At points prior to two hours, [3H]-CpG levels are higher than DNP-
[3H]-CpG levels.  However the opposite was seen after two hours with DNP-[3H]-CpG levels 
sustained above [3H]-CpG levels.  [3H]-CpG showed a large drop in serum levels between 1 
to 2 hours.  Serum levels persisted past the measured time points for both groups.  A 
noncompartmental analysis was performed using WinNonlin 5.2.1 (Pharsight Corporation, 
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Cary, NC) to elucidate the elimination half-life (Figure 2.2).  Analysis using the method of 
residuals gives an elimination half-life estimate of 1.08 hours for [3H]-CpG.  This estimate is 
comparable to that obtained from intravenous data.4  This analysis indicates the ascending 
portion of the serum data actually represents the elimination phase while the descending 
portion represents the rate-limiting absorption.  In contrast, the descending portion of the 
DNP-[3H]-CpG plot represents rapid absorption whereas the terminal portion of the plot 
represents slow elimination.  Data for DNP-[3H]-CpG results in an estimate of 715 hours 
which is consistent with the substantial increase in elimination half-life as seen with 
intravenous data for DNP-[3H]-CpG compared to [3H]-CpG. 
Figures 2.3 and 2.4 present the tissue distribution profile of [3H]-CpG and DNP-[3H]-
CpG, respectively.  In both cases, injection site radioactivity levels were initially high, but 
diminished over time, a finding consistent with SC administration.  Almost no radioactivity 
was detected in the heart and lungs.  At all time points, both ODNs were found in the liver 
and kidneys.  [3H]-CpG was found in the spleen at low levels while DNP-[3H]-CpG levels 
were almost zero. As expected, levels of [3H]-CpG in the tumor were low.  However, a key 
observation was seen with DNP-[3H]-CpG.  Even at later time points, negligible levels of 
DNP-[3H]-CpG were detected in the tumor tissue.  This finding is in stark contrast to the 
results seen with IV data in which accumulation of DNP-[3H]-CpG in the tumor was as high 
as 30% of the injected dose.  This suggests that the two routes of administration may utilize 
two different mechanisms for presentation of CpG to target cells. 
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Discussion 
 During this experiment, anti-DNP antibody titer levels were confirmed to be high by 
ELISA.  Based on the available results, the time to peak serum concentration for DNP-[3H]-
CpG nor the maximum serum level could not be concretely established since we do not have 
data at the 1 hour time point.  However, noncompartmental analysis using the method of 
residuals was employed to determine whether flip-flop kinetics was present.  Based on the 
results, [3H]-CpG was shown to exhibit flip-flop kinetics in which the absorption phase,, 
represented by the declining portion of the concentration-time profile, is much slower than 
the elimination rate constant, represented by the ascending portion of the curve.  This result 
is typical of extravascular administration, especially in cases involving depot injections such 
as SC administration.   In contrast, the initial declining portion of the DNP-[3H]-CpG data 
represents a rapid absorption while the flattened portion indicates slow elimination.  As 
shown in the DNP-[3H]-CpG profile, serum levels of DNP-[3H]-CpG after two hours are 
maintained higher than [3H]-CpG.  This additionally supports the argument that antibodies 
can be used as systemic carriers to mediate ODN half-life in the circulation.4  Analysis of the 
DNP-[3H]-CpG data is also supportive of the above conclusion since the elimination half-life 
was over 700 hours which is much higher than that of [3H]-CpG. 
Detection of [3H]-CpG in the kidney and liver agrees with the typical renal and 
hepatic clearance observed for many synthetic ODNs.15  Since DNP-[3H]-CpG is assumed to 
exist as an IC, it is unlikely that the levels found in the kidney and liver are due to the same 
clearance mechanisms but rather Fc receptor-mediated association with glomerular epithelial 
cells16,17 or Kupffer cells.18-20  Accumulation in the spleen is likely due to ODN uptake by 
plasmacytoid DCs.21  Negligible accumulation of [3H]-CpG in the tumor tissue was expected 
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and coincided with the high radioactivity levels in the liver and kidneys.  This is consistent 
with results from IV administration.4   However, the remarkable observation that DNP-[3H]-
CpG did not accumulate in the tumor greatly differs from IV data.  This may be a result of 
multiple reasons.  Intravenously administered DNP-CpG is 100% bioavailable to circulation 
and a higher concentration has immediate access to the tumor periphery.  DNP-CpG 
administered subcutaneously exhibits lower serum concentrations due to a depot effect at the 
injection site thereby limiting serum concentration and the extent of tumor accumulation.  
Tumor accumulation is also restricted since DNP-CpG and its IC with anti-DNP will be first 
subject to lymphatic drainage and transport before reaching the circulation22.  As a result, it 
could well be immediately processed by DCs found in the lymph nodes.23  Ultimately, the 
amount of DNP-CpG that does reach the circulation may be low such that a high percentage 
will be processed by blood DCs.  In fact, these outcomes may be beneficial to CpG delivery 
since a clinical regimen can potentially be established to use a lower dose and lower dosing 
frequency.  Based on the accumulation results, it can be proposed that, depending on the 
route of administration, the EPR effect may or may not be vital in the processing of CpG-
containing immune complexes.  In fact, the EPR effect may play a minimal, if any, role in 
anti-cancer effects upon SC administration.  More discussion on this subject can be found in 
Chapter III.  
 
 
Conclusions 
 
 The similarities in the pharmacokinetic and biodistribution profiles of [3H]-CpG and 
DNP-[3H]-CpG suggest that both may also demonstrate similar anti-tumor efficacy.  
However, pharmacokinetic analysis of serum data indicates that DNP-CpG would have 
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greater anti-tumor efficacy.  Based on these findings, subcutaneous delivery of DNP-CpG in 
pre-immunized hosts exhibits potential in anti-cancer therapy.  In one respect, however, low 
tumor accumulation may hinder DC-mediated anti-tumor effects if the EPR effect plays a 
major role in CpG delivery.  Although the EPR effect may play a role in the intravenous 
administration of DNP-CpG, distribution of DNP-CpG to the tumor was minimal upon 
subcutaneous administration and it is unlikely that the EPR effect offers a significant 
contribution to CpG delivery and subsequent anti-tumor effects.  For SC administration, 
delivery to the lymphatics and also sustained serum levels may prove to be substantial in 
activating anti-tumor immune responses via DCs not residing in the tumor locale.  Further 
studies focused on biodistribution of CpG ODNs to the draining lymph nodes will help to 
establish a mechanism of action.  Current observations suggest that CpG delivery could 
involve two distinct physiological mechanisms for delivery and processing depending on the 
route of administration. 
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Figure 2.1. Serum pharmacokinetics of free CpG and DNP-CpG after a single subcutaneous 
injection.  Oligonucleotides are tritium labeled.  Red is free CpG.  Blue is DNP-CpG.  All 
mice were immunized against DNP.  Data are presented on a log-linear scale.  The inset 
depicts PK profiles from 0 to 6 hours.  Concentrations are expressed as the mean and bars 
represent the standard deviation (SD).  n = 4 mice per time point. 
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Figure 2.2.  Noncompartmental analysis of serum pharmacokinetic data for [3H]-CpG and 
DNP-[3H]-CpG.  The upper plot is [3H]-CpG and the lower plot is DNP-[3H]-CpG.  
Elimination and absorption rate constants were obtained, respectively, via the method of 
residuals using the shaded area which was determined based on the best-fit predicted line fit 
to the raw data (red circles). 
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Figure 2.3. Biodistribution of free CpG after a single subcutaneous dose.  Tumor-bearing 
mice were pre-immunized against DNP and anti-DNP antibody titer was confirmed to be 
high during the study.  The colored bars represent the average percent of the total injected 
dose at given time points after the given dose ± SD.  Violet, Red, Orange, Green, Blue, and 
Pink represent 5, 10, 20, 60, 120, and 240 minutes, respectively. n = 3 mice per time point. 
As expected, a large amount was retained at the injection site and a very trivial amount 
accumulated in tumor tissue.  
 48
 
0
5
10
15
20
25
30
35
heart lungs spleen liver kidneys tumor inject site
%
ID
 
o
f [
3H
]-D
N
P-
Cp
G
 
 
Figure 2.4. Biodistribution of DNP-CpG after a single subcutaneous dose.  Tumor-bearing 
mice were pre-immunized against DNP and anti-DNP antibody titer was confirmed to be 
high during the study.  The colored bars represent the average percent of the total injected 
dose at given time points after the given dose ± SD.  Violet, Red, Orange, Green, Blue, and 
Pink represent 0.5, 2, 6, 12, 24, 48, 72 hours, respectively. n = 3 mice per time point. 
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Abstract 
 Routes of administration have been a limiting factor for CpG oligodeoxynucleotide 
(ODN) monotherapy for tumor growth inhibition and only recently has CpG monotherapy 
been shown to be effective in a murine tumor model after intravenous (IV) delivery.  Success 
has been attributed to utilization of IgG as an endogenous drug carrier for delivery of CpG 
ODNs to dendritic cells, especially those around tumor locales.  The subcutaneous (SC) route 
has shown great potential, but current studies have shown poor efficacy when CpG therapy is 
given without additional intervention.  In the following studies, we compared the anti-tumor 
effects between SC and IV administration of dinitrophenylated CpG (DNP-CpG) in DNP-
immunized BALB/c mice bearing subcutaneous CT26 colorectal tumors.  Secondly, we 
compared anti-tumor efficacy between free, non-haptenized CpG and DNP-CpG in the same 
animal model.  Subcutaneous administration of DNP-CpG was highly effective in tumor 
inhibition and showed equivalent response to intravenous administration when anti-DNP titer 
was high.  Increased dosing intervals resulted in tumor regression.  However, loss of 
therapeutic efficacy was evident when antibody titer was low.  Free CpG failed to show 
comparable anti-tumor activity when administered subcutaneously.  In all cases, DNP-ss, a 
DNP derivative of an ODN which has an identical nucleotide composition as CpG 1826 but 
has a scrambled and non-immunostimulatory sequence, failed to exhibit any anti-tumor 
activity.  Collectively, these results show the potential of the subcutaneous route of CpG 
ODN administration for anti-cancer monotherapy by means of in situ formation of immune 
complexes in vivo. 
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Introduction 
 To date, CpG ODNs used in monotherapy for tumor control suffer from lack of an 
effective route of administration. Although intra- and peri-tumoral injections have been 
effective in murine models,1 these routes limit the use of CpG ODNs in humans to only 
specific types of cancer.  Intravenous administration is often used because the drug achieves 
100% bioavailability such that maximum absorption and distribution to target site is ensured.  
However, IV delivery of any ODN results in rapid clearance from the circulation to the 
clearing organs, particularly the liver and kidneys.2  Intravenous dosing also subjects ODNs 
to dilution and non-specific binding to serum proteins, especially those with a 
phosphorothioate backbone.3  Only recently, upon use of an endogenous protein carrier, have 
we shown that CpG can be effective in anti-cancer therapy after IV administration.4   Our 
novel drug delivery strategy utilizes a chemical conjugate of CpG to a 2,4-dinitrophenyl 
(DNP) hapten such that it forms a monovalent immune complex (IC) with an anti-DNP IgG 
antibody in animals which are pre-immunized against DNP.   
 Since a substantial amount of endogenous IgG is found in the interstitial tissue in 
dynamic equilibrium with plasma, approximately at 25% of the plasma concentration5, we 
reasoned that a significant amount of SC dose of DNP-CpG would exist as IC at the injection 
site in the tissue. These complexes will be drained to lymphatics and eventually discharged to 
general circulation where a high anti-DNP titer is available for further IC formation. Due to 
the failed attempts of intravenous free CpG ODNs delivery, the SC route of administration 
has been previously studied although not established for monotherapy.6-8  Subcutaneous 
administration offers many practical benefits. Intravenous and intramuscular (IM) injections 
require skilled personnel whereas SC injections can be easily self-administered by a patient, 
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painless, and administered at many different sites on the body.  In fact, many drugs such as 
morphine, insulin, and heparin have been highly successful through SC administration.  The 
SC route is very promising especially since it allows for slow release from the injection site 
and for accumulation in the lymph nodes where many DCs are located. 
Development of tumor vaccines using CpG ODNs monotherapy has not been 
successful although use of CpG ODNs as adjuvants9-11 or in conjunction with additional 
therapies show clinical promise.12,13  In exactly the same murine tumor model as ours, CpG 
failed to elicit anti-tumor activity after subcutaneous administration.1  In the following 
studies, we utilize our novel delivery strategy in two series of experiments to compare the 
effectiveness between SC and IV administration for CpG monotherapy and to determine 
whether SC administration of DNP-CpG exhibits improved therapeutic response over free 
CpG in mice which were pre-immunized with DNP.  
 
Experimental Procedures 
General Procedures and Materials 
 All reagents were purchased from commercial sources and were used without further 
purification unless otherwise noted.  For each experiment, 30 female BALB/c mice, five 
weeks of age, were purchased from The Jackson Laboratory (Bar Harbor, ME).  All mice 
were housed in the UNC Eshelman School of Pharmacy Kerr Hall Animal Facility according 
to NIH guidelines. All procedures were approved by the UNC Institutional Animal Care and 
Use Committee.  Molecular biology-grade water, phosphate buffered saline (PBS), sodium 
carbonate, thimerosal, complete Freund’s adjuvant (CFA), and incomplete Freund’s adjuvant 
(IFA) were purchased from Sigma-Aldrich (St. Louis, MO).  Hammersten-grade casein was 
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purchased from Research Organics (Cleveland, OH).  Dinitrophenylated keyhole limpet 
hemocyanin (DNP-KLH) and dinitrophenylated bovine serum albumin (DNP-BSA) were 
purchased from Calbiochem (San Diego, CA).  Critoseal, non-heparanized microcapillary 
tubes, Nunc MaxiSorp 96-well flat-bottom plates, and Tween 20 were purchased from 
Thermo Fisher Scientific (Waltham, MA). O-phenylenediamine dihydrochloride (OPD) and 
Stable Peroxidase Substrate Buffer, and were purchased from Pierce (Rockford, IL).  Goat 
anti-mouse IgG-peroxidase conjugate was purchased from Southern Biotech (Birmingham, 
AL).  BALB/c-derived colon carcinoma CT26 cells were purchased from American Type 
Culture Collection (ATCC) (Manassas, VA) and cultured in Dulbecco's Modified Eagle 
Medium (DMEM) with low (1 g/L) glucose supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin.  All cell culture reagents, including trypsin-EDTA 
and Hank’s Balanced Salt Solution (HBSS) were purchased from Invitrogen (Carlsbad, CA).  
Cell culture vented flasks and conical tubes were purchased from Corning, Inc. (Corning, 
NY).  CpG 1826 (free CpG), dinitrophenylated CpG 1826 (DNP-CpG), and control DNP-
ODN 1982 (DNP-ss) were synthesized with a phosphorothioate backbone and provided in 
lyophilized form by Dr. Rowshon Alam of the Nucleic Acid Core Facility of the Program 
Project Grant in Pharmacodynamics of Genes and Oligonucleotides at the University of 
North Carolina at Chapel Hill.  ODNs were diluted in PBS before use. 
 
Vaccine Preparation and Active Immunization 
 To prepare the primary vaccine, 20 mg of DNP-KLH was dissolved in 10 ml of 
endotoxin-free water to give a 2 mg/ml solution.  Prior to vaccination, an equal volume of 
CFA was added.  The mixture was emulsified by vortexing at maximum rpm for 15 minutes 
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using a multi-tube vortexer (VWR, West Chester, PA).  Secondary vaccines were prepared 
similarly, but replacing CPA with IFA. 
Thirty BALB/c mice were immunized intraperitoneally with 200 µl of freshly 
prepared primary vaccine.  A booster injection was given two weeks later using 200 µl of the 
secondary vaccine.  In the first pharmacodynamic experiment, a second booster injection was 
given five weeks after the first booster to maintain a high antibody titer. 
 
Antibody Titer 
 In each experiment, four mice were selected for antibody titer bleeds and the same 
four mice were used throughout the entire duration of the experiment.  Samples were 
collected before immunization to establish background antibody levels and were then 
collected every two weeks.  Fifty-microliter blood samples were collected into non-
heparanzied microcapillary tubes by tail clip.    Blood samples were allowed to clot at room 
temperature (RT) for up to 1 hour and were then centrifuged at 12,700 x g for five minutes 
using an IECMicro-MB Centrifuge (Thermo Fisher Scientific, Waltham, MA).  Serum 
fractions were collected and diluted 10-fold in PBS, pH 7.4.  Anti-DNP IgG titers were 
determined by the enzyme-linked immunosorbent assay (ELISA).  Nunc MaxiSorp 96-well 
plates were coated with 125 µl per well of a 10 µg/ml DNP-BSA solution in 0.1 M sodium 
carbonate buffer, pH 9.6 and incubated overnight at 4oC.  Wells were washed in triplicate 
with 250 µl per well of PBS containing 0.1% v/v Tween 20 (PBS-T washing buffer) and then 
blocked with a mixture of 0.5% w/v casein and 0.02% w/v thimerosal in PBS, pH 7.4 
(blocking buffer) for two hours at RT.  Wells were then washed again in triplicate and 
incubated with 50 µl of serially diluted serum samples and incubated for 2 hours at RT.  
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Serum samples were serially diluted from 5x102 to 106 at half-log increments in PBS.  After 
a triplicate wash, wells were incubated with 125 µl of goat anti-mouse IgG-peroxidase 
conjugate diluted in PBS for two hours at RT.  Wells were washed in triplicate and incubated 
with 125 µl per well of a 1 mg/ml OPD solution in Stable Peroxidase Substrate Buffer for 20 
minutes at room temperature.  The colorimetric reaction was terminated by the addition of 
125 µl per well of 1.8 N sulfuric acid.  Absorbance at 492 nm was measured on a Bio-Rad 
3550 Microplate Reader.  Best-fit sigmoidal curves were obtained from plotting absorbances 
vs. log dilution factors using GraphPad Prism 4 (La Jolla, CA).  Titer levels were obtained as 
EC50 values from the midpoint of each sigmoidal curve. 
 
Tumor Inoculation, Tumor Measurements and Dosing Schedule 
 Four to five weeks after primary vaccination, DNP-immunized mice were inoculated 
with 2.5x105 CT26 cells suspended in 100 µl HBSS into the right flank.  Tumor growth was 
monitored daily.  Measurements were performed using an electronic digital caliper.  Tumor 
volumes were calculated based on the formula for an ellipsoid: length x width2 x π/6.  
Treatments began nine days after inoculation when tumor sizes were between 75 to 150 mm3. 
 In the first experiment, 24 mice were divided evenly into three test groups: DNP-ss 
via IV (negative control), DNP-CpG via IV (positive control), and DNP-CpG via SC (test).  
Here, DNP-ss is a scrambled nucleotide sequence of composition identical to that of CpG 
1826 and is known as 1982 in the literature.14  Mice dosed intravenously were given a 108 µg 
bolus dose of the treatment in 100 µl of PBS into the tail vein.  Mice dosed subcutaneously 
were given a 108 µg dose of the treatment into the left flank (contralateral to the tumor).  
This quantity is equivalent to 100 µg of un-derivatized CpG. Three doses were given in 
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seven-day intervals followed by three additional doses at three-day intervals for a total of six 
doses.  Tumors were monitored daily and measured every two or three days.  Mice were 
euthanized when tumors exceeded 2.0 cm in any dimension. 
 In the second series of experiments, 29 mice were divided into three test groups: 
DNP-ss (negative control, n=9), free CpG (test, n=10), and DNP-CpG (test, n=10).  Five 
108-µg doses in 100 µl of PBS were administered subcutaneously into the left flank of each 
mouse every five days.  Tumor monitoring, measurements, and animal euthanasia were as 
described above. 
 
Statistical Analysis 
 Using Van der Waerden normal scores, a nonparametric pair-wise comparison test 
was performed to determine if there were statistical differences in tumor volumes between 
each group at each day.  Statistical analyses were performed with the SAS statistical software 
by Dominic T. Moore of the UNC Lineberger Comprehensive Cancer Center Biostatistics 
and Data Management. 
 
Results 
 In the first of two series of animal experiments, high anti-DNP antibody titer levels 
were established before initiation of treatments and persisted at least up to the third dose 
(Figure 3.1).  Over a six-week period subsequent to the first booster injection, the titer 
continuously increased.  This was in agreement with our previous finding (E. Palma, 
“Antibody-Mediated Systemic Delivery of CpG Oligonucleotides for Solid Tumor 
Immunotherapy,“  PhD Dissertation submitted to the University of North Carolina, 2006).  
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Animals were inoculated with tumor cells while the anti-DNP titer was still increasing.  
Figure 3.2 shows that IV dosing of the DNP-haptenized non-immunostimulatory control 
ODN, DNP-ss, was unable to elicit any therapeutic response.  As expected, tumor growth 
proceeded in an exponential-like manner when no therapeutic intervention was provided.  
However, IV administered DNP-CpG exhibited anti-tumor efficacy.  Most notable is that SC 
administration of DNP-CpG was not only highly effective, it was comparable to the IV route 
and even resulted in almost complete tumor regression after only two doses.  When tumor 
growth rate noticeably increased, dosing frequency was increased to every three days and 
once again partial tumor regression was achieved.  Note that in this experiment, a third 
immunization was made to keep anti-DNP antibody titer high throughout the treatment 
schedule. 
 In a separate, second series of experiments, the second booster immunization was 
omitted.  Figure 3.3 shows that anti-DNP antibody titers were high at the start of dosing, but 
started to fall between dose 2 and 5 since the second booster was omitted.  The failure of the 
SC administration of DNP-ss to hinder tumor development, much like the failure of the IV 
administration, was as expected.  This negative control group of mice was sacrificed earlier 
than the treatment groups following UNC IACUC guidelines since tumors reached a 
maximum allowable size and quickly became ulcerated. A notable inhibitory response, 
however, was seen with SC-administered free CpG.  Nonetheless, the best response came 
from DNP-CpG treatments.  Although inhibited by free CpG treatments, tumor growth still 
continued to steadily increase.  In contrast, DNP-CpG was clearly able to induce partial 
regression at early time points, an observation consistent with the previous experiment.  
Tumor growth was also more variable, in favor of the DNP-CpG treatments, with occasional 
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durations of nearly complete tumor inhibition as can be seen by the almost plateau-like areas 
in Figure 3.3.  However, when anti-DNP titers dropped substantially, DNP-CpG treatments 
became less effective at tumor growth inhibition.  At this point, tumor growth rate was rapid 
and mirrored the growth rate with the free CpG treatment group. 
 
Discussion 
  
DNP-ss has the same nucleotide composition as the therapeutic CpG but the sequence 
is arranged such that no CpG motifs are present.  Since DNP-ss has no immunostimulatory 
function, but are structurally similar to regular CpG, it was selected as a negative control as 
commonly found in the literature.15,16  As shown in Figure 3.2, IV dosing of DNP-ss failed to 
prevent tumor growth although it may have circulated for a long period of time, confirming 
the literature.1  The SC administration of DNP-ss also failed to elicit a response.  Results 
from IV dosing of DNP-CpG in the first series of experiments are almost identical to the 
results we reported recently4 and confirms the potential use of IV administration for CpG 
monotherapy in a clinical setting.   
The ability of SC administration to achieve such similar effects may be attributed to 
multiple reasons.  Since plasma antibody levels are normally in constant equilibrium with 
tissue antibody levels, it is reasonable to believe that an IC can be readily formed at or near 
the injection site.  An SC injection is also a type of depot injection especially for 
macromolecules, which would allow for a prolonged and constant release of DNP-CpG over 
time.  Thirdly, drainage of DNP-CpG from the injection site occurs via the lymphatic system.  
DNP-CpG will first encounter lymph nodes before reaching the systemic circulation.  
Therefore, DNP-CpG can be presented in a more direct manner to dendritic cells and 
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macrophages in the lymph node, which would initiate the adaptive immune response leading 
to anti-tumor activity via its endosomal TLR9 receptors. The effect exhibited by SC 
administration of free CpG can be explained by similar reasoning.  In contrast to IV dosing, 
CpG injected via the SC route is not subject to immediate systemic elimination and has the 
opportunity to first reach the DC targets.  The only difference is that free CpG can be readily 
taken up by dendritic cells via fluid-phase endocytosis for processing rather than by receptor-
mediated means, a subject discussed in Chapter IV. 
The importance of our antibody carrier system is evident in the second series of 
experiments where one booster immunization was omitted (Figure 3.3).  A clear inverse 
correlation is observed between antibody titer and tumor volume.  Partial tumor regression 
and higher inhibition of tumor growth rate attests to the enhanced anti-tumor effects of 
immune complexation over free CpG treatments, the implication being the importance of 
maintaining a high fraction of the oligonucleotide in the form of an immune complex.  
Statistical analysis indicates that tumor volumes were not statistically different when 
treatments began.  Differences were deemed significant if p-values were less than 0.05.  
DNP-CpG already showed statistical significance at day 2 when compared to DNP-ss, but no 
statistical difference was seen with free CpG until day 7.  Except for those days and at day 
16, which was borderline significant, tumor volumes were statistically significant between 
DNP-CpG and free CpG. 
 
Conclusions 
Our antibody-based carrier system for CpG ODN has great potential for clinical use.  
Not only can the intravenous route of injection now be used for effective CpG treatment, the 
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subcutaneous route of administration is shown to be just as effective.  However, because of 
the possibility of highly variable titer levels, this system must be further developed to avoid 
inter-individual variability and even intra-individual variability depending on progression of 
disease.  Nevertheless, these results strongly support an approach to utilize pre-existing 
endogenous antibodies or to devise other development means such that pre-immunization of 
patients can be avoided completely.  The ability of SC administration of DNP-CpG to 
perform as effectively as the IV route is promising for CpG development and is also 
remarkable for many reasons.  The advantages of using a long-acting depot injection include 
increased cost-effectiveness, medication compliance due to reduction in the frequency of 
dosing, as well as more consistent serum concentrations. 
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Figure 3.1.  Anti-DNP antibody titer levels in BALB/c mice after immunization against 
DNP-KLH.  A booster was given two weeks and seven weeks after the primary vaccination 
to maintain high antibody titer in order to ensure quantitative complexation of DNP-CpG to 
antibody.  Titers are expressed as means ± SD. n=4. 
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Figure 3.2.  Comparison of tumor growth inhibition between subcutaneous and intravenous 
dosing of DNP-CpG in immunized mice.  Tumor growth inhibition by intravenous DNP-ss 
(negative control, n=10), intravenous DNP-CpG (n=10), and subcutaneous DNP-CpG (n=10) 
administration in DNP-immunized, CT26 tumor-bearing mice.  Tumor volumes were plotted 
against time in days after administration of the first dose.  Data are expressed as means ± SD. 
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Figure 3.3.  Comparison of tumor growth inhibition between free CpG and DNP-CpG during 
subcutaneous dosing in immunized mice.  Tumor growth inhibition by subcutaneous 
administration of DNP-ss (negative control, n=9), free CpG (n=10), and DNP-CpG (n=10) in 
DNP-immunized, CT26 tumor-bearing mice.  Tumor volumes were plotted against time in 
days after administration of the first dose.  Data are expressed as means ± SD.  Anti-DNP 
IgG titer measurements are overlaid and expressed as means ± SD. 
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 70
Abstract 
 Dendritic cells (DCs) are the most potent antigen-presenting cells involved in CpG 
oligodeoxynucleotide-based therapies.  To enhance delivery of CpG to DCs, we have 
modified an immunostimulatory CpG through conjugation to a 2,4-dinitrophenyl (DNP) 
hapten such that it forms a monovalent immune complex (IC) with an anti-DNP IgG 
antibody.  Our in vivo IC system has been effective in tumor growth inhibition in a murine 
model. We attributed the observed anti-tumor activity to the enhanced delivery of the 
monovalent IC to DCs via FcγRI-mediated endocytosis.  In this study, DCs were treated with 
our IC and with free CpG to compare the extent of CpG uptake and the extent of dendritic 
cell activation using flow cytometry.  We showed that uptake of free CpG was greater than 
immune-complexed CpG.  However, expression of DC activation markers was greater with 
IC treatment.  Inhibition of Fcγ receptors resulted in expression levels comparable for both 
IC and free CpG treatments.  Taken together, the data appear to support the importance of 
FcγRI in the receptor-mediated uptake and processing of CpG immune complexes for the 
effective enhancement of DC activation. 
 
Introduction 
 Plasmacytoid dendritic cells (pDCs), a subset of immature DCs, and B cells are the 
only human immune cells known to constitutively express TLR9.1  When activated by CpG 
oligodeoxynucleotides (ODNs), pDCs excrete cytokines and chemokines which activate cells 
of the innate immune system which can confer direct anti-tumor effects.2-4  DC stimulation 
also results in increased expression of co-stimulatory molecules such as CD80 and CD86 to 
signal proliferation of T-cells, particularly type 1 helper T cells (TH1).  In the presence of 
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tumor-associated antigens, DCs can process these antigens for major histocompatibility 
complex (MHC) presentation to T cells.  Both the co-stimulatory and MHC signals are 
required for successful activation of T cells.5   Suggestive of DC involvement in CpG 
therapy, intralymphatic administration considerably improved therapeutic response to CpGs6 
while another study was able to treat large murine tumors using combined DC and CpG 
therapy.7  Still others have attempted to use receptor-mediated delivery of antigens to DCs 
for anticancer applications.8   These findings warrant the use of CpG ODN for DC activation, 
ultimately resulting in T cell effector function,9 in cancer immunotherapy.  As such, delivery 
of CpG to DCs would benefit greatly using a drug delivery system. 
 A major concern with current synthetic delivery systems, especially based on 
macromolecular assemblies, is the inherent immunogenicity.10  Even protein-based 
therapeutic ICs and antibodies can elicit immune responses and attempts have been made to 
minimize their immunogenicity.11  The ideal drug delivery system must not only carry intact 
cargo to the target location but also avoid activating the immune system or undesired 
neutralization that leads to elimination from the body.  Herein lies the enormous potential of 
endogenous antibodies in CpG and general delivery.  Furthermore, DCs not only express 
TLR9 receptors, they also express cell-surface Fc receptors such as FcγR which bind the Fc 
domain of immunoglobulins.  This implicates the potential for antibodies to be used for 
delivery to DCs. 
 We developed antibody-based drug delivery strategy in the treatment of solid tumors 
and explore the possible mechanistic effects involved. Our approach, shown to be highly 
effective, consists of IV bolus injection of CpG that was derivatized with 2,4-dinitrophenol 
(DNP) to tumor-bearing mice that had been pre-immunized against the DNP hapten.12  
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Furthermore, we will show later, contralateral subcutaneous (SC) injections of DNP-CpG 
were also found to be effective in the same mouse model.   
Although immune complexes are known to enhance antigen presentation by DCs13, 
cellular mechanisms of non-crosslinking, monovalent CpG immune complexes are unclear.  
One possible explanation of these successful outcomes was that we were able to provide 
facilitated uptake of ICs by DCs through the Fc receptor expressed on pDCs.  We also 
propose that our ICs activate DCs more effectively than free CpG.  This hypothesis arises 
because we expect ICs to enter the cell efficiently via FcγRI resulting in facilitated 
interactions with TLR-9 in the endosome.  Here, we present some supportive evidence. 
 
 
Experimental Procedures 
General Procedures and Materials 
All reagents were purchased from commercial sources and were used without further 
purification unless otherwise noted.  C57BL/6 mice 6 to 8 weeks of age were purchased from 
Charles River Laboratories. All mice were housed in the UNC Eshelman School of Pharmacy 
Kerr Hall Animal Facility according to NIH guidelines. All procedures were approved by the 
UNC Institutional Animal Care and Use Committee.  RPMI 1640 cell culture media was 
used for marrow harvesting.  Dendritic cells were cultured in complete media comprised of 
RPMI 1640 supplemented with fetal bovine serum (FBS) (10% v/v), 1x antibiotic-
antimycotic solution, 1x non-essential amino acid solution, 1000 U/ml recombinant mouse 
granulocyte macrophage-colony stimulating factor (rmGM-CSF), and 1000 U/ml 
recombinant mouse interleukin 4 (rmIL-4).  All media components were from Invitrogen 
except for cytokines which were purchased from R&D Systems.  Non-fluorescent DNP-CpG 
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1826 (DNP-CpG) and control ODN 1982 (DNP-scramble) were synthesized and provided 
lyophilized by Dr. Rowshon Alam of the Nucleic Acid Core Facility of the Program Project 
Grant in Pharmacodynamics of Genes and Oligonucleotides.  Fluorescein isothiocyanate 
(FITC)-conjugated DNP-CpG was custom synthesized by Midland Certified Reagent 
Company (Midland, TX).  ODNs were resuspended in molecular biology-grade water 
(Sigma-Aldrich) and concentrations were confirmed by UV spectrophotometry.  Anti-DNP 
monoclonal IgG1 was produced by the Tissue Culture Facility at the UNC Lineberger Cancer 
Center using 1B7.11 hybridoma cells and was purified before use.  Purity of antibodies and 
oligonucleotides were confirmed by polyacrylamide gel electrophoresis.  All test treatments 
were prepared using endotoxin-free, cell-biology grade water (Sigma-Aldrich).  
Lipopolysaccharide (LPS) and human serum albumin were purchased from Sigma-Aldrich.  
Mouse IgG2a was purchased from Bethyl Laboratories (Montgomery, TX).  Uptake and 
activation experiments were performed using a BD FACSCanto flow cytometer.  
Fluorophore-conjugated antibodies against DC surface markers and Fc Block, a rat anti-
mouse IgG2b monoclonal antibody which is used to block Fc receptors, were purchased from 
BD Biosciences (San Jose, CA). 
 
Dendritic Cell Harvesting and Culture 
Mouse bone marrow-derived DCs were harvested and cultured as described 
elsewhere14 with some modifications.  Briefly, femurs and tibias were collected from 
C57BL/6 mice, disinfected with 70% ethanol, washed twice with PBS, and stored in RPMI 
1640. Marrow was flushed out of the bones, centrifuged at 300 x g for 5 minutes, and the 
supernatant was discarded.  Cells were resuspended in ACK Lysis buffer (Invitrogen) by 
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vortexing to lyse all red blood cells followed by addition of RPMI 1640.  Cells were 
centrifuged again and the supernatant discarded.  Cells were resuspended in RPMI 1640, 
transferred to T-75 flasks, and incubated at 37oC for 2 hours.  Media was then discarded and 
cells were incubated with complete media.  Complete media was used for subsequent media 
changes on day 2 and 4.  On day 6, loosely adherent and suspended cells were harvested for 
experimental treatments.  Cells were confirmed to be >95% CD11c-positive using a 
phycoerythrin (PE)-conjugated anti-CD11c antibody. 
 
Dendritic Cell Uptake 
 Dendritic cells were transferred to a 96-well plate and seeded at a density of 2x105 
cells per well in 100 µl of complete media.  Cells were incubated for 15-min, 30-min, 45-
min, 1-hr, or 2-hr durations with either free FITC-DNP-CpG or FITC-DNP-CpG with anti-
DNP mIgG1.  In addition, a series of cell samples were pre-incubated with 5 µl of Fc Block 
for 30 minutes at 4oC prior to incubation with treatments.  For treatments, cells were 
incubated in a 200 µl total volume with a 1 µg/ml equivalent to underivatized CpG.  Of the 
total mass used, 50% was FITC-DNP-CpG and the rest was unlabeled DNP-CpG.  After 
incubation, cells were transferred to a 5 ml Falcon tube (BD Biosciences, San Jose, CA) to 
which 10% v/v of 0.4% Trypan Blue solution was added to quench cell membrane-bound  
fluorescence.  Unquenched non-fluorescent DNP-CpG was used as a negative control while 
unquenched FITC-DNP-CpG was used to determine maximum total fluorescence. 
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Dendritic Cell Activation 
 Dendritic cells were transferred to a 96-well plate and seeded at a density of 2x105 
cells per well per 100 µl complete media.  Cells were incubated with a 200 µl total volume 
with the following final concentrations for 0, 6, 12, or 24 hours: 
1. Complete media only 
2. DNP-CpG (1 µg/ml relative to CpG) 
3. DNP-scramble (1 µg/ml relative to CpG) 
4. anti-DNP IgG (1 molar equivalent to DNP-CpG) 
5. DNP-CpG + anti-DNP IgG (immune complex) 1:0.25 molar ratio 
6. DNP-CpG + anti-DNP IgG (immune complex) 1:1 molar ratio 
7. DNP-CpG + anti-DNP IgG (immune complex) 1:5 molar ratio 
8. DNP-scramble + anti-DNP IgG 1:1 molar ratio 
9. Fc Block then IC 1:1 molar ratio 
10. Fc Block then DNP-scramble + anti-DNP IgG 1:1 molar ratio 
11. Fc Block then media 
12. DNP-CpG + Human Serum Albumin  
13. Human Serum Albumin (based on mass equivalent of IgG from 1:1 IC) 
14. DNP-CpG + Mouse IgG2a 1:1 molar ratio 
15. Mouse IgG2a (1 molar equivalent to DNP-CpG) 
16. LPS (0.1 µg/ml) 
 
For IC formation, DNP-CpG was incubated with anti-DNP antibody for 1 hour at 
37oC.  At the end of the incubation intervals, all samples were centrifuged at 300 x g for 5 
minutes and the supernatant was decanted. Cells were washed with two 500 µl volumes of 
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FBS Stain Buffer (BD Biosciences) and resuspended in 200 µl of the buffer.  Cells were then 
incubated with 5 µl of Fc Block for 30 minutes at 4oC followed by addition of various 
fluorophore-conjugated antibodies against various DC surface activation markers.  One series 
of cells was then incubated with 1 µl of FITC-conjugated anti-CD86 antibody, 1 µl of PE-
conjugated anti-CD80 antibody, and 1 µl of allophycoerythrin-conjugated anti-CD40 
antibody.  Another series of cell samples were incubated with 1 µl of FITC-conjugated anti-
CD86 antibody and 1 µl PE-conjugated anti-I-Ab (MHC II marker for the C57BL/6 mouse 
strain).  Cells were allowed to incubate in the dark for 30 minutes at 4oC followed by two 
500 µl washes with buffer. Cells were finally resuspended in 500 µl of buffer for flow 
cytometry. In all cases, we ran isotype controls with rat IgG2a,κ-FITC and rat IgG1,κ-APC to 
establish the absence of non-specific staining of DCs in all of the treatments.   
 
Results 
Dendritic Cell Uptake 
 As shown in Figure 4.1, non-fluorescent DNP-CpG treatments resulted in no levels of 
fluorescence while unquenched FITC-DNP-CpG established maximum possible fluorescence 
levels for each incubation period.  Cells incubated with FITC-DNP-CpG at 4oC followed by 
quenching were used to establish baseline levels of intracellular fluorescence.  Maximum 
uptake of FITC-DNP-CpG and FITC-IC occurred around 1 hour.  FITC-DNP-CpG 
treatments exhibited the most intracellular fluorescence across all time points.  Across all 
incubation durations, except for the 2-hour incubation, the FITC-IC also had high 
intracellular fluorescence although approximately 10% lower than FITC-DNP-CpG.  
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Incubation of cells with Fc Block prior to treatments resulted in drastic decreases in 
intracellular fluorescence levels for both FITC-DNP-CpG and FITC-IC treatments. 
 
Dendritic Cell Activation 
For activation studies, only CD86 activation results are shown in Figure 4.2, as they 
were also representative of those obtained for all aforementioned other markers.  Since LPS 
is known as a potent activator of DCs and can fully activate DCs between 16 to 24 hours, it 
was used as a positive control.  Cells incubated with media only had a maximum baseline 
activation level around 35%.  Free CpG and free anti-DNP antibody can independently 
activate DCs, but the non-immunostimulatory ODN, DNP derivative of the scrambled 
sequence 1982, does not.  Incubation of DNP-CpG with either albumin or IgG2a only activate 
to free DNP-CpG levels.  Pre-incubation of cells with Fc Block notably decreases DC 
activation levels equivalent or lower than free CpG levels.  Most notable, however, is that our 
immune complex (IC) shows increased dendritic cell activation over free DNP-CpG.  A 1:1 
immune complex was found to be the most effective while a large excess of antibody 
displayed levels of activation similar to free CpG and free antibody.  
 
Discussion 
Dendritic Cell Uptake 
 FITC-DNP-CpG showed highest intracellular fluorescence across all time points 
(Figure 4.1).  This is most likely due to the high endocytic capacity of dendritic cells.15  
Although slightly lower, FITC-IC also displayed great intracellular uptake.  A lower 
intracellular fluorescence may be explained as its internalization could have been restricted to 
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FcγRI-mediated endocytosis.  Lower IC fluorescence levels are not thought to be a result of 
complexation with the antibody, but this has yet to be confirmed.  Nonetheless, the high 
intracellular fluorescence, especially after 1 hour, can attest to the efficient uptake of ICs.  
After two hours, intracellular levels of FITC-DNP-CpG and FITC-IC drop dramatically.  
Cellular processing and degradation of treatment compounds can be expected at this point.  
Increase in fluorescence of both Fc Block treatments at two hours appears to be also 
consistent with the possibility that the cells are likely eliminating Fc Block and restoring 
normal endocytic function.  The decrease seen with FITC-DNP-CpG may be due to the 
hindrance of ODN in accessing endocytic routes.  Use of Fc Block dramatically decreases 
fluorescence for FITC-IC as expected.   
 
Dendritic Cell Activation   
The increased activation of the IC over free DNP-CpG is not considered to be simply 
due to an additive effect since levels of free DNP-CpG alone and anti-DNP antibody alone 
are rising from 12 to 24 hours whereas IC levels from 12 to 24 are very similar (Figure 4.2).  
In addition, IC activation should not decrease with increasing antibody concentration if 
activation is thought to be an additive effect of antibody and DNP-CpG.  DNP-CpG with 
either human serum albumin or an unrelated antibody (mouse IgG2a) only has the same level 
of activation as DNP-CpG alone.  This is consistent with the finding that albumin and IgG2a 
alone only exhibit baseline activation. Therefore, our specific anti-DNP IgG antibody is vital 
for the increased activation which also suggests that FcγRI-mediated endocytosis is involved. 
 Multiple treatments were included to specifically elucidate the importance of our 
hypothesized FcγRI-mediated uptake.  At a 1-to-0.25 molar ratio of DNP-CpG to anti-DNP 
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antibody, enhanced DC activation was seen.  However, except for the positive control, the 
1:1 molar ratio gave the maximum DC activation. The data shows that an excess (5 molar 
equivalent) of anti-DNP antibody resulted in the worse activation response between all three 
ratios examined.  At a lower antibody ratio, a lower amount of DNP-CpG existed as an 
immune complex and, therefore, was not efficiently endocytosed and processed by DCs.  At 
the other extreme, an excess of antibody resulted in low activation most likely due to 
competitive inhibition.  Based on this reasoning, a 1:1 ratio would be ideal since a 
quantitative amount of DNP-CpG would be bound and mainly immune complexes are 
occupying FcγRI receptors.  Results also further indicate the involvement of FcγRI since Fc 
Block also significantly lowers the activation of both DNP-CpG + anti-DNP antibody and 
DNP-scramble + anti-DNP antibody.  When comparing DNP-scramble + anti-DNP-antibody 
with Fc-block + DNP-scramble + anti-DNP antibody, lower activation is also noted for the 
latter treatment.  These findings all independently suggest that FcγRI must be important for 
processing of ICs.   
As a footnote, the data presented in this section as well as the previous section were 
obtained from single determination of each activation marker albeit each entailed counting of 
over 104 cells.  Ideally, the effect of each treatment should have been assessed at least 
triplicate determinations.  In summary, the present data are preliminary in nature and warrant 
further investigation.   
 
Conclusions 
DNP-CpG can freely be taken up by DCs via macropinocytosis whereas ICs must 
enter the cell via FcγRI.  This is supported by our finding that free FITC-DNP-CpG treatment 
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had a higher intracellular fluorescence compared to IC treatment.  However, although ICs are 
limited to this single uptake mechanism and intracellular fluorescence was lower, we find 
that ICs are able to stimulate DC activation better than free DNP-CpG.  It is also important to 
note that even though free DNP-CpG exhibits good uptake and activation in vitro, these 
promising results are not translated to in vivo therapeutic effects.12  Taken together, our 
findings suggest that FcγRI plays an important role in the cellular uptake of ICs and that our 
IC is effective in enhancing levels of dendritic cell activation. 
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Figure 4.1.  Dendritic cell uptake of free CpG and DNP-CpG.  Dendritic cell uptake as 
measured by fluorescence in dendritic cell samples after 0.25, 0.5, 0.75, 1, and 2-hour 
incubations with: free FITC-DNP-CpG on ice (red); free FITC-DNP-CpG (blue); FITC-IC 
(yellow); Fc Block then free FITC-DNP-CpG (orange); Fc Block then FITC-IC (pink).  
Samples were quenched with 10% v/v of a 0.4% Trypan Blue solution to examine 
intracellular fluorescence.  Cells were incubated at 37oC unless otherwise noted. 
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Figure 4.2.  Dendritic cell activation by free CpG and DNP-CpG with and without anti-DNP 
antibodies.   These CD86 results are also representative of those obtained from CD40, CD 
80, and MHC II.  Dendritic cell activation as measured by surface activation marker 
expression levels after 0, 6, 12, and 24-hour incubation periods with: media only (white); 
DNP-CpG (blue); DNP-scramble (blue lines), anti-DNP antibody alone (green); ICs with 1:1 
DNP-CpG:antibody ratios (red); DNP-scramble with antibody (red lines); Fc Block followed 
by IC (violet); Fc Block followed by DNP-scramble with antibody (violet lines); DNP-CpG 
with albumin (yellow); DNP-CpG with IgG2a (turquoise); and LPS (black).  In all cases, 1.08 
µg/ml DNP-CpG was used to activate cells.  Negative controls with Fc block alone, albumin 
alone, and IgG2a alone yielded baseline activation at all time points studied (data not shown).  
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CHAPTER V 
 
CONCLUSIONS AND FUTURE STUDIES 
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Recent promising results obtained with intravenous delivery of CpG 
oligodeoxynucleotides (CpG-ODNs) for solid tumor immunotherapy1 warranted further 
study to establish additional means of administration and to elucidate mechanistic immune 
responses.  In the present studies, we have analyzed the pharmacokinetic and 
pharmacodynamic effects of dinitrophenylated CpG (DNP-CpG) after subcutaneous 
administration into DNP-immunized, tumor-bearing mice.  We found a sustained release of 
DNP-CpG from the injection site and enhanced circulation in the serum.  Although there was 
low accumulation of DNP-CpG in tumor tissue, significant anti-tumor activity was observed.  
Here we confirmed that antibody complexes with haptenized CpG ODNs exhibit anti-cancer 
effects in pre-immunized animals.  Low antibody titers resulted in significant loss of 
therapeutic activity by DNP-CpG thereby confirming the important role of antibodies to 
mediate CpG delivery.  These studies establish the opportunity for SC administration in CpG 
ODN monotherapy.  We also propose based on these results that a lower dose of DNP-CpG 
per injection could be used to achieve similar anti-tumor efficacy.   
 
To determine possible mechanistic means by which anti-tumor activity ensued upon 
SC administration of our treatment, we examined the ability of our monovalent immune 
complex to promote uptake of DNP-CpG into dendritic cells through FcγRI-mediated 
endocytosis and to subsequently enhance activation of dendritic cells (DCs).  We found that 
while free CpG uptake was higher than IC uptake, DC activation was enhanced in the latter 
case.  Blocking of Fc receptors using the Fc block reagent resulted in a significant decrease 
in IC uptake by DCs.  Our study also confirms that DC activation by our system is specific 
and activation enhancement requires DNP-CpG with an anti-DNP antibody.  Attempts to 
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activate DCs using non-immunostimulatory ODNs or other proteins were not as effective as 
the IC.  The decrease in DC activation markers after blocking FcγRI-receptor uptake supports 
the involvement of FcγRI-mediated processing of ICs. 
 Although we previously reasoned that the success of our delivery strategy could be 
partially attributed to the enhanced permeability and retention (EPR) effect, pharmacokinetic 
and pharmacodynamic results, such as the low levels of DNP-CpG detected in the tumor 
tissue and the ability of free CpG to hamper tumor growth, suggest otherwise.  In the case of 
intravenous administration, the EPR effect may be the mechanism although activation of 
DCs in the spleen may contribute to anti-tumor effects.  In the case of subcutaneous 
administration, no EPR effect is expected because the DNP-CpG levels in the systemic 
circulation at any given time remains low and accumulation in the tumor periphery is also 
very low.  We propose that the mechanism of action may be the direct activation of DCs in 
the draining lymph nodes.  Elevated interstitial fluid pressure (IFP) in the tumor vicinity is a 
barrier to macromolecular drug delivery which means that IC accumulation in the tumor 
periphery could be limited.2  Any accumulation would also only be transient and retention 
would require receptor-ligand binding.3  Even if a sufficient level of binding was to occur, 
chaotic and impaired tumor lymphatics could limit dendritic cell migration from the tumor 
periphery to the lymph nodes, thus preventing antigen-presentation to T cells.  As such, the 
ability of the immune complex to target DCs through general lymphatic and/or systemic 
circulation may be a more reasonable explanation.  Dendritic cells, in this case, can find 
tumor antigen released into the systemic circulation due the IFP phenomenon.  CpG 
stimulation of DCs also leads to the stimulation of natural killer cells which may also be 
involved in anti-tumor activity.  Since there is still much speculation as to the processes 
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involved in the immune response upon CpG stimulation, further mechanistic studies are 
necessary.  Nonetheless, our results lead to the important discovery that the mechanism of 
action in CpG processing is dependent on the route of delivery.   
 
 These promising results warrant further development of antibody-based systems for 
CpG delivery.  For patients who have compromised immune function due to prior treatments 
or due to the negative effects of disease progression itself, pre-immunization against a hapten 
may not be acceptable.  Ex vivo complexation is a possible alternative although previous 
unpublished preliminary data from our lab has suggested that the IC may not be maintained 
in a dynamic in vivo setting.  An alternative would then be to chemically conjugate a CpG 
ODN directly to an antibody molecule.  However, this may only work using the host’s own 
endogenously produced antibodies since use of ex vivo murine and chimeric monoclonal 
antibodies can exhibit poor half-lives4,5 or altered affinity to Fc receptors upon storage.6  The 
ideal method of development would then be to use an already existing endogenous antibody 
which is known to recognize a particular hapten or epitope.  As a result of vaccines received 
during childhood and adulthood, antibodies against certain pathogens are ever-present in the 
systemic circulation although concentrations may be insufficient.  The anti-Gal antibody is 
the only naturally occurring antibody known to exist in large amounts in all humans.7  The 
anti-Gal antibody recognizes the α-gal carbohydrate epitope which is normally absent in 
humans.  A system can be envisioned then in which CpG is conjugated to the α-gal epitope 
instead of DNP.  In fact, recent work has utilized in vivo anti-Gal-based immune complexes 
for DC delivery of a vaccine.8  Further development would also allow co-administration of 
CpG with tumor antigen as a therapeutic anti-cancer vaccine. 
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Through the present studies it has become apparent that multiple aspects must be 
investigated to establish primary mechanistic processes involved, particularly with the 
relevance of the EPR effect towards in vivo systems.  Mechanistic studies can be 
accomplished by multiple techniques.  Rather than in vitro activation, DC activation levels 
after treatment can be studied from acquisition of DCs from lymph nodes for flow cytometry.  
Immunohistochemistry of normal and tumor tissue can reveal the type and extent of 
lymphocyte involvement.  Additionally, studying the impact of FcγRI-deficiency on IC 
processing in a pre-immunized, tumor-bearing mouse model would be of great interest.  
FcγR-knockout mice are available for such studies.  IC uptake and activation of DCs can be 
further confirmed by utilizing FcγRI-deficient DCs cultured from the bone marrow of the 
same mouse strain.9  Effector cell involvement can be analyzed by looking at T-cell 
proliferation in spleens and infiltration into tumor tissue. 
 
 Collectively, our findings promote the use of CpG monotherapy for clinical use in 
cancer therapy although cellular toxicity and immunological memory should first be studied.  
Additional routes of administration could be established, such as intranasal or intradermal 
delivery where DCs are definitively located as a first-line defense against pathogenic 
invasion, for treatment of various diseases.  Our systemically delivered ICs could result in 
reduced CpG ODN therapeutic dose and dosing frequency.  Treatment of occluded and 
metastasized tumors may also be possible without further intervention with invasive surgery 
or toxic chemotherapy.  Successful outcomes of these studies will undoubtedly bring about 
an accelerated development of CpG-based immunotherapy, possibly in synergy with other 
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treatment modalities, for various human diseases in addition to cancer such as infectious 
diseases, allergic conditions, and asthma.10  We also envision a general application of using 
antibodies as a drug carrier, not as a targeting ligand, to delivery of other small nucleic acids. 
 91
References 
(1) Palma, E.; Cho, M. J. Improved systemic pharmacokinetics, biodistribution, and 
antitumor activity of CpG oligodeoxynucleotides complexed to endogenous 
antibodies in vivo. J. Control. Release 2007, 120, 95-103. 
 
(2) Stohrer, M.; Boucher, Y.; Stangassinger, M.; Jain, R. K. Oncotic pressure in solid 
tumors is elevated. Cancer Res. 2000, 60, 4251-4255. 
 
(3) Berk, D. A.; Yuan, F.; Leunig, M.; Jain, R. K. Direct in vivo measurement of targeted 
binding in a human tumor xenograft. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 1785-
1790. 
 
(4) Ober, R. J.; Radu, C. G.; Ghetie, V.; Ward, E. S. Differences in promiscuity for 
antibody-FcRn interactions across species: implications for therapeutic antibodies. 
Int. Immunol. 2001, 13, 1551-1559. 
 
(5) Goodman, G. E.; Beaumier, P.; Hellström, I.; Fernyhough, B.; Hellström, K. E. Pilot 
trial of murine monoclonal antibodies in patients with advanced melanoma. J. Clin. 
Oncol. 1985, 3, 340-352. 
 
(6) Bertolotti-Ciarlet, A.; Wang, W.; Lownes, R.; Pristatsky, P.; Fang, Y.; McKelvey, T.; 
Li, Y.; Li, Y.; Drummond, J.; Prueksaritanont, T.; Vlasak, J. Impact of methionine 
oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol. 
Immunol. 2009, 46, 1878-1882. 
 
(7) Galili, U.; Rachmilewitz, E. A.; Peleg, A.; Flechner, I. A unique natural human IgG 
antibody with anti-alpha-galactosyl specificity. J. Exp. Med. 1984, 160, 1519-1531. 
 
(8) Abdel-Motal, U. M.; Wigglesworth, K.; Galili, U. Mechanism for increased 
immunogenicity of vaccines that form in vivo immune complexes with the natural 
anti-Gal antibody. Vaccine 2009, 27, 3072-3082. 
 
(9) Barnes, N.; Gavin, A. L.; Tan, P. S.; Mottram, P.; Koentgen, F.; Hogarth, P. FcγRI-
Deficient Mice Show Multiple Alterations to Inflammatory and Immune Responses. 
Immunity 2002, 16, 379-389. 
 
(10) Dittmer, U.; Olbrich, A. R. M. Treatment of infectious diseases with 
immunostimulatory oligodeoxynucleotides containing CpG motifs. Curr. Opin. 
Microbiol. 2003, 6, 472-477. 
APPENDIX 
 
CYTOKINE LEVELS DURING CpG TREATMENTS 
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Previous investigations have showed that alteration of cytokine genes or direct 
administration of various cytokines could result in anti-cancer effects.  However, certain 
dismal results have been consistent with the difficulties associated with cytokine cancer 
therapy, where systemic administration of cytokines produces significant toxicity side effects 
at an effective dose. Success may be obtained by mimicking the paracrine functions of 
cytokines in the tumor microenvironment.1,2  We attempted to demonstrate that our delivery 
strategy mimics local infection or inflammation in the tumor tissue. This is a reasonable 
hypothesis given that CpG is derived from bacterial DNA and that we measured as much as 
20% of the total intravenously injected dose in the tumor tissue.3   Since SC administration 
showed little tumor accumulation, we were curious to see whether the anti-tumor activity 
could have been due to a cytokine effect.  Nonetheless, it has proved to be rather difficult to 
present experimental evidence. 
 
Elevated level of serum cytokines from CpG administration may not be directly 
related to anti-tumor activity.1,2 This notion was experimentally supported as follows. Three 
groups of BALB/c mice each with 5 to 6 mice received either: (A) contralateral subcutaneous 
(SC) dosing of DNP-CpG in DNP-immunized mice, (B) SC dosing of free CpG to non-
immunized mice, and (C) peritumoral injection of CpG also to non-immunized mice 
(positive control). Four hours after each of the four weekly administrations, approximately 50 
µl of blood was withdrawn via tail nick and processed to serum. Then IL-12 concentrations 
were determined using a commercially obtained BD OptEIA® kit (BD Biosciences). 
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Although the data presented in Figure A.1 are on only one cytokine, the following 
conclusion can be made. In all cases, a tremendous IL-12 response was seen compared with 
the basal level (the first small bar only visible on Group C).  Although subcutaneous 
administration of free CpG generates a higher level of IL-12 compared to DNP-CpG, tumor 
inhibition studies showed that DNP-CpG treatment results in a better anti-tumor response.  
This finding supports the notion that local production of cytokines, not their systemic levels, 
is the key to anti-tumor activity. 
 
The above set of data supports only a negative conclusion. Next, we sought after 
direct evidence for the very premise upon which the proposed studies are developed: i.e., our 
CpG delivery systems are able to induce proinflammatory cytokines locally in tumor tissue 
although the CpG is administered via bolus IV or SC. In essence, our delivery system mimics 
local bacterial infection that would induce immediate innate immune response. The 
experiments dealt with 3 groups of CT26 tumor-bearing BALB/c mice, each with 4 animals.  
 
Group A consisted of DNP-immunized mice receiving DNP-CpG intravenously 
(test). In B non-immunized mice received free CpG intravenously (negative control) whereas 
Group C received free CpG peritumorally (positive control). A single dose of 100 µg IV or 
20 µg PT was administered when tumor becomes approximately 30~100 mm3. The latter 
dose was chosen based on the fact that in the literature PT dose typically ranges from 3~10 
µg4, 10 µg5, 20 µg6, 20~40 µg7, to as high as 100 µg8 and the finding that our formulation 
delivered to tumor tissue approximately 20% ID at the time of cytokine assay, i.e., 4 hrs after 
administration.3 
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Surgically removed tumor and normal tissue contralateral to tumor were 
homogenized with T-PER® Tissue Protein Extraction Reagent, 10 ml per gram tissue, 
supplemented with protease inhibitor cocktail (Pierce, Rockford, IL), as described 
elsewhere.5  The supernatant and serum were serially diluted in PBS for ELISA with BD 
OptEIA® ELISA Kits: TNF-α, IFN-γ, IL-6, IL-12, and GM-CSF.  It is known that these 
cytokines become overexpressed in tumor tissue upon repeated PT daily dosing of free CpG 
especially when tumor burden is low.5 Briefly these cytokines are indicative of the following 
phenomena in innate immunity triggered by CpG ODNs9: TNF-α and IL-12, DC activation; 
IFN-γ, NK cell activation; IL-6, B cell growth and differentiation; and GM-CSF, DC 
stimulation. 
 
As shown in Figure A.2, there is some indication our approach produced more pro-
inflammatory cytokines in tumor tissue than free CpG injected IV. Due to a small number of 
animals tested in each group (n = 4) and wide inter-subject variations, however, there were 
no statistically significant differences based on t-test analysis among the test treatments for 
all five cytokines measured (p>0.05). This must be because we analyzed the sample just after 
one treatment. The amount of CpG delivered via ICs was simply insufficient to create a 
situation to mimic local inflammation.  
 
In the prior study, we attributed the lack of statistically significant differences in 
various cytokine levels among the three treatments to the fact that we measured them after 
only one single dosing. Since then we have repeated the experiment with five daily doses. 
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When the tumor volume was between 20 to 75 mm3, four mice in each of three groups 
received a daily dose of: test group A (red), 50 µg IV to immunized mice; negative control B 
(green), 50 µg IV; and positive control C (gray), 10 µg intratumoral. Four hours after the fifth 
and final dose, animals were sacrificed and the tumor was processed for ELISA.  
 
As shown in Figure A.3, IL-12 is the only cytokine that appeared to be significantly 
more produced in the tumor with the test formulation. Even here, the standard deviation was 
so large and the number animals used was small (n=4), the p value was as high as 0.31 for 
the test formulation-negative control comparison. Similarly TNF-α production in tumor with 
the test formulation is greater than that of negative control. However, once again, the p value 
was close to 0.38. Within experimental error, the other two cytokines did not show any 
modality-dependence. 
 
The inter-subject variations we observed were in the same magnitude as previously 
reported.5  The cytokine study in this manuscript was what prompted us to analyze cytokine 
levels in our own model.  In retrospect, we should not have run this series of experiments. 
Instead, we should have characterized cell infiltration via immunohistochemistry, an 
important subject of investigation in the future.   The complexities involved with cytokine 
management suggest that this method of anti-cancer treatment may not be the ideal treatment 
modality.
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Figure A.1.  Comparison of serum IL-12 concentrations upon various single-dose CpG 
treatments.  Serum concentration of IL-12 found 4 hrs after dosing of; (A) DNP-CpG in 
DNP-immunized mice via SC route, (B) CpG to non-immunized mice via SC route, and (C) 
CpG to non-immunized mice via PT route. In all cases, mice harbored CT26 tumors of 50 to 
150 mm3 of starting size. In each group there are 5 bars: the first one represents IL-12 of 
mice not dosed (baseline level). It is almost non-detectable but barely visible in Group C. 
The 2nd (filled in black) through the 5th bars (filled with dots) represent the IL-12 level after 
the 1st through the 4th weekly dosing, respectively. The red horizontal lines represent the 
average values in each group of 5 or 6 mice. 
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Figure A.2.  Comparison of cytokine levels in tumor, muscle, and serum upon single-dose 
CpG treatments.  Three pro-inflammatory cytokine levels found in tumor tissue, contralateral 
muscle tissue, and serum after single administration of: A (red), DNP-CpG to pre-immunized 
mice IV; B (green), free CpG IV; and C (grey), free CpG PT. In all cases, n = 4 and tumor 
was 30~100 mm3 in size when injection took place. Normalization is in terms of tumor size 
based on the size-dependent T-PER buffer volume used. 
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Figure A.3.  Comparison of cytokine levels in tumor tissue after multiple dosing of CpG 
treatments.  Four pro-inflammatory cytokine levels found in tumor tissue after five daily 
administrations of: A (red), DNP-CpG to pre-immunized mice IV; B (green), free CpG IV; 
and C (grey), free CpG IT.  In all cases, n = 4 and tumor was 20-75 mm3 in size when 
injections took place. Four hours after the fifth/final dose, animals were sacrificed and the 
tumor was processed for ELISA. Normalization is in terms of tumor size based on the size-
dependent T-PER buffer volume used. 
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